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 The Regulation Of Lactate Metabolism In Epithelial-Mesenchymal Transition Of  
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Denisse Guadalupe Tafur-Cotrina, Ph.D. 
University of Connecticut, 2017 
 
Lactate is both a metabolite of glycolysis, and a component of several signaling pathways. 
Although recent studies indicate that lactate is a critical regulator of cancer development, very 
little is known about lactate metabolism in the context of metastatic cancer. Epithelial-to 
mesenchymal transition (EMT) promotes metastasis by inducing invasive properties in epithelial 
tumors. To determine whether EMT induces metabolic alterations, we have studied two epithelial 
breast cancer cell lines (MCF-7 and BT-474) and their respective EMT-induced mesenchymal 
progeny (MCF-7 M and BT-474 M) for changes in lactate metabolism. Metabolic analysis 
revealed that EMT induced an enhanced glycolytic profile in mesenchymal breast cancer cells 
along with the overexpression of glucose transporters (GLUT3, GLUT12), lactate dehydrogenases 
(LDHA, LDHB) and monocarboxylate transporter 4 (MCT4). In contrast, epithelial breast cancer 
cells preferentially use oxidative phosphorylation (OXPHOS) to produce ATP. These aerobic 
epithelial breast cancer cells expressed the monocarboxylate transporter 1 (MCT1) and maintained 
significantly higher intracellular levels of lactate and pyruvate. The strong expression of the lactate 
importer MCT1 in epithelial breast cancer cells may involve the ERα-inducible GATA3 
transcription factor. GATA3 is central to normal breast development, and is expressed in ERα 
positive breast cancer.  Using the UCSC Genome Browser, we detected a specific GATA3 binding  
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site in the DNAse-hypersensitive region within the promoter of MCT1 gene, and found that 
knockdown of GATA3 represses MCT1 expression.  We also observed that the endogenous lactate 
receptor, G-protein coupled receptor 81 (GPR81), was highly expressed in epithelial breast cancer 
cell lines and hormone-positive breast cancer tumors but was suppressed in post-EMT 
mesenchymal cancer cells or triple negative breast cancer (TNBC) tumors. GPR81 regulated 
MCT1 expression and lactate uptake in epithelial breast cancer cells and its expression was crucial 
for cell proliferation and survival under nutrient limited conditions. This study provides an 
overview of specific metabolic changes induced by EMT in two independent and substantially 
different epithelial breast cancer cell lines. In addition, we propose GPR81 as a potential 
prognostic marker and therapeutic target in hormone positive epithelial breast cancer.  
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I. THE BREAST  
i. Anatomy  
The female breast represents a gland that is specialized in the synthesis, secretion and delivery of 
milk to the newborn. This complex tissue is composed of lobules (milk producing glands), ducts 
(milk-carrying tubes), blood vessels, lymph nodes and stroma (adipose and connective tissue 
surrounding the ducts and lobes). The breast is organized into 15 to 20 lobes, each lobe has 20 to 
40 lobules which consist of clusters of alveoli containing mammary secretory epithelial cells. 
Lobules are connected to very small ducts that merge into a unique duct for each lobe (2-4.5 cm 
long) that ends in its own opening at the nipple. The dark area of skin surrounding the nipple that 
contains sweat and sebaceous glands is called the areola. Although the breast is mature after puberty, 
the breast tissue remains inactive until pregnancy1,2. 
ii. Development 
The breast undergoes many changes in structure and function during a woman’s lifetime in 
response to hormonal stimuli1. From birth through childhood, the mammary gland remains small 
and immature3. Later during puberty, hormones produced by the ovaries and pituitary gland cause 
the breast to grow and mature.  This maturation process is called branching morphogenesis and 
involves enlargement of the milk ducts by expansion of the epithelial ductal cells4. During 
pregnancy, prolactin and placental lactogen induce the alveolar epithelial cells to proliferate and 
differentiate into milk-secreting cells. During lactation, milk is secreted by epithelial cells and 
accumulated in the lumen of the alveoli. Oxytocin, stimulated by suckling infant, causes the 
contraction of the surrounding myoepithelial cells that moves the milk through the ductal tree and 
to the nipple. Upon weaning, the reduction of hormonal levels stops milk production and promotes 
apoptosis of epithelial cells, an event referred to as involution1,4. 
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II. BREAST CANCER 
i. Epidemiology  
Breast cancer is the most commonly diagnosed cancer in women and it is one of the leading 
causes of cancer deaths in the world. According to the World Health Organization, breast cancer 
was responsible for 571,000 deaths in 2015. In the US, the National Cancer Institute estimates 
255,180 new cases (15% of all new cancer cases) along with 41,070 deaths (6.8% of all cancer 
deaths) for breast cancer in 2017. The incidence of breast cancer and mortality increase 
dramatically with age. Breast cancer is most frequently diagnosed in middle-aged and older 
women among women aged 55-64 (median age at diagnosed is 62)5.  
The percent of female breast cancer deaths is highest among women aged 55-64 (median age 
at death is 68). Women who are diagnosed at an advanced age may be more likely than younger 
women to die of the disease. Five-year relative survival depends on the stage at which the cancer 
is diagnosed. There are better chances of surviving five years after being diagnosed when the 
breast cancer is detected earlier. Five-year relative survival is 99% for localized stage, 85% for 
regional stage, and 27% for distant stage.  
ii. Classification  
Breast cancer is a complex disease with multiple subtypes, each characterized by distinct 
morphology, molecular profile, clinical behavior and treatment options. The majority of breast 
cancer tumors (95%) are derived from the inner lining epithelium of the ducts or the lobules of the 
breast. Breast cancer originating from the ducts are known as ductal carcinomas, while those 
originating from the lobules are known as lobular carcinomas.  The most common type of breast 
cancer is ductal carcinoma. Ductal and lobular carcinomas are divided into two types based on 
their histological appearance: 1. in situ, noninvasive neoplastic cells that are limited to the 
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epithelial layer; 2. invasive carcinoma, which denotes a cancer that has moved through the basal 
lamina of the epithelial layer and has invaded the surrounding stroma. Ductal invasive carcinoma 
is the most common form of breast cancer and represents 80% of all breast cancer diagnoses6. 
Breast cancers are classified into three clinical subgroups based on similarities in the gene 
expression profile and molecular classification. The most common subtype accounts for 70-80% 
of all the cases is estrogen/progesterone receptor positive (ER+/PR+) known as luminal breast 
cancer. The second subtype is human epidermal growth factor 2 positive (HER2+ overexpressed 
and amplified), which accounts for 15% of all the cases. Both luminal and HER2+ respond to 
hormone and antibody therapy respectively. The third subtype is the basal-like or also known as 
triple-negative (ER-, PR-, HER2-), which accounts for 15% of all the cases and responds to 
chemotherapy and polymerase inhibitors7.  
 
III. EPITHELIAL-MESENCHYMAL TRANSITION  
i. Definition and Classification  
Epithelial cells are polarized cells with strong adherent cell-cell and cell-basal lamina junctions. 
The basement membrane separates the epithelial lining from the stroma or connective tissue. In 
contrast, mesenchymal cells display fibroblast-like morphology, lack of cell-cell adhesions and 
have the ability to migrate and invade adjacent tissues.  The process by which epithelial cells de-
differentiate into mesenchymal cells is called epithelial-mesenchymal transition (EMT). EMT is a 
biological process that involves a set of multiple and dynamic transitional states between epithelial 
and mesenchymal phenotypes with a reverse process called mesenchymal-epithelial transition 
(MET)8.  
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EMT programs have been classified into 3 types; type 1 relates to embryo formation and 
development; type 2 is related to tissue regeneration, organ fibrosis and wound healing; and type 
3 is associated with cancer progression and metastasis8,9.  
Type 3 EMT can be activated in epithelial cancer cells, causing them to downregulate adhesion 
junctions, acquire invasive properties and develop metastatic growth characteristics. Epithelial 
cancer cells that undergo full or partial EMT participate in cancer progression including invasion 
through the basement membrane, migration through stroma and intravasation followed by 
transport through the lymphatics or circulation. In addition, EMT confers a stem cell phenotype 
and resistance to cell death, immunotherapy and chemotherapy8,10.  
ii. EMT-mediated changes in gene expression 
During EMT, cancer cells oscillate between intermediary phases of epithelial and mesenchymal 
phenotypes8. Epithelial cancer cells that undergo complete EMT suffer complex cellular and 
molecular alterations such as changes in morphology, acquisition of motility and changes in gene 
expression profile that ultimately promote invasiveness and metastasis. These events involve 
reduction in epithelial proteins like cell-cell adhesion molecule E-cadherin, accompanied by the 
upregulation of mesenchymal proteins such as Vimentin, N-cadherin, fibronectin and α-smooth 
muscle actin which facilitate migration and invasion8,11.  
iii. EMT-inducing transcription factors  
EMT is driven by several transcription factors including zinc-finger binding transcription factors 
SNAIL1and SNAIL2; zinc finger E-box–binding homeobox ZEB1 and ZEB2; and basic-loop-
helix Twist in respond to a microenvironmental stimuli12. These EMT-inducing transcription 
factors repress expression of genes associated with cell-cell adhesion, while activating genes 
associated with the mesenchymal phenotype10. SNAIL1, SNAIL2 and TWIST repress the 
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expression of E-cadherin, tight junction proteins (claudin and occludin) and epithelial-specific 
intermediate filament proteins (cytokeratins)10,11. These factors activate the expression of 
fibronectin, N-cadherin and genes encoding extracellular matrix proteins (collagen and matrix 
metalloproteinases - MMPs) and drive cancer stem cell features11. ZEB factors are known to 
repress directly E-cadherin and the tight junction associated signaling proteins ZO-1, and activate 
N-cadherin and MMPs10,11.  
iv. EMT-inducing signaling pathways 
EMT is induced in response to stimuli from the tumor microenvironment, like growth factors, 
cytokines, hypoxia, and contact with the surrounding extracellular matrix (ECM)11. These stimuli 
activate signaling pathways including transforming growth factor-β (TGF-β), Notch, WNT/β-
catenin, Hedgehog and receptor tyrosine kinases which in turn activate EMT-transcription factors 
to initiate the EMT process11,12.  
TGFβ is the most well-characterized signaling pathway that induces EMT by acting through 
SMAD-mediated and non-SMAD signaling11,12. SMAD-mediated signaling activates SMAD 
factors (SMAD 2/3/4), resulting in an activated complex that interacts with several transcription 
factors (SNAIL1, SNAIL2 and TWIST) to regulate genes involved in the EMT process. In 
addition, SMADs directly activate the expression of some mesenchymal genes encoding 
fibronectin, vimentin and collagen. TGFβ also induces non-SMAD signaling pathways like NF-
κB, Par6, small GTPases, PI3K/AKT/TOR and MAP kinase that regulate cytoskeleton 
organization, cell survival, migration and invasion contributing to the EMT process13.  
Receptor tyrosine kinases are activated by several growth factors including epidermal growth 
factor (EGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and vascular 
endothelial growth factor (VEGF), leading to the RAS–RAF–MEK–ERK MAPK signaling 
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cascade to induce EMT. On the other hand, Notch, WNT/β-catenin and Hedgehog pathways 
promote downregulation of E-cadherin levels11,13. 
Hypoxia is as an example of a major external stimulus that leads to changes in mitochondrial 
function, leading to the upregulation of hypoxia-inducible factor 1-α (HIF1α), hepatocyte growth 
factor (HGF), SNAI1 and TWIST1 and activation of the Notch or NF-κB pathways12,13. 
Inflammation also promotes EMT, involving cytokines such as interleukin-6 and TNF-α11. 
Additionally, TNF-α promotes cancer invasion, angiogenesis and stemness properties associated 
with EMT programs11–13. The pathways that induce EMT also involve microRNAs (miRNAs)11,12. 
Specific miRNAs target mRNAs encoding adhesion junction and polarity complex proteins and 
signaling mediators. For example, miR-194 represses N-cadherin expression, preventing cell 
migration and invasion. The miR-200 family suppresses the EMT process by targeting 
ZEB1/ZEB2 and maintaining E-cadherin expression12.  
 
IV. Metabolic Reprogramming  
Cancer cells undergo metabolic alterations to adapt to the tumor microenvironment. Collectively 
these alterations are referred as metabolic reprogramming, which confers growth and/or survival 
advantages on cancer cells14. Metabolic reprogramming of cancer cells is associated with increased 
nutrient uptake including glucose and glutamine, along with alterations of intracellular metabolic 
pathways like glycolysis and tricarboxylic acid (TCA) cycle. In some cases, metabolic 
reprogramming allows cancer cells to accumulate precursor molecules needed during rapid cell 
proliferation, and to produce ATP as well as antioxidant metabolites, such as NADPH. In addition, 
metabolic reprogramming  promotes access to diverse metabolites that serve as cofactors or 
substrates for enzymes involved in signaling pathways and gene regulation15. Finally, cancer cells 
that undergo metabolic reprogramming are able to alter the composition of their tumor 
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microenvironment, affecting the behavior of neighboring cells like tumor-associated fibroblasts, 
endothelial cells, and innate and adaptive immune system cells to favor tumor growth and 
dissemination14,16. 
i. Mitochondrial Respiration 
Most differentiated and nonproliferating cells metabolize glucose into pyruvate via glycolysis, and 
then most of that pyruvate enters into mitochondria where it is converted to acetyl-CoA, which is 
completely oxidized to carbon dioxide (CO2) in the tricarboxylic acid (TCA) cycle. The electrons 
released from this oxidation process are transferred to NAD+ and FAD+, to generate 3 NADH and 
one FADH2. These reduced cofactors are used to create a proton gradient across the mitochondrial 
membrane by a pathway called the electron transport chain (ETC). The energy stored in this 
gradient is used to drive ATP synthesis by a process called oxidative phosphorylation (OXPHOS). 
In OXPHOS, oxygen must be present to receive electrons from the protein complexes as it is the 
final electron acceptor. A maximum of 32 molecules of ATP (2 from the TCA cycle and 30 from 
OXPHOS) are generated per two molecules of acetyl-CoA entered into the TCA cycle.  
In a tumor there are regions with different nutrient and oxygen concentrations, driving selection 
for those cancer cells that are able to adapt their metabolism to changing external factors. 
Relatively quiescent cancer cells that reside within an oxygenated tumor microenvironment utilize 
glucose preferentially for mitochondrial acetyl-CoA generation, which is then subjected to 
oxidation in the TCA cycle and later OXPHOS for ATP production14. In fact, studies in breast and 
cervical cancer cells showed that mitochondrial OXPHOs contributes more than 70% and 90% 
respectively in overall ATP generation under normal conditions17. On the other hand, aggressive 
and rapidly proliferating cancer cells switch to a glycolytic metabolism to generate ATP regardless 
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of the presence of oxygen, a phenomenon referred to as "the Warburg effect" or aerobic 
glycolysis18. 
ii. Aerobic glycolysis or “Warburg effect” 
In the 1920s, the German physiologist Otto Warburg made an observation regarding tumor 
metabolism. He showed that tumor tissue metabolizes more glucose compared to nonproliferating 
normal tissue resulting in high lactate production even in the presence of oxygen. This observation 
has come to be known as the “Warburg effect” or aerobic glycolysis. Most recently, studies have 
shown that proliferating cancer cells exhibit increased glucose uptake and glycolytic flux14. Most 
of the pyruvate from glycolysis is converted to lactate rather than be transported into the 
mitochondria to maintain oxidative phosphorylation. Although glycolysis has a low efficiency to 
produce ATP (2 molecules per glucose), the rate of ATP synthesis is faster compared to OXPHOS. 
Consequently, by increasing glucose uptake and glycolytic flux, the amount of ATP produced from 
glycolysis can surpass the amount produced from OXHPHOS. Additionally, glucose catabolism 
provides metabolic intermediates needed for rapid cell growth, and reduces oxygen dependency 
and reactive oxygen species (ROS) production. Furthermore, lactate generated by glycolytic 
cancer cells acidifies the extracellular microenvironment which facilitates tumor cell migration 
and invasion19. Recent studies have shown that the Warburg effect phenomenon is typical in 
proliferating tumor cells and also in some stromal cells like cancer-associated fibroblasts 
(CAFs)14,18.  
iii. Reverse glycolysis or “Reverse Warburg effect” 
In a single tumor there are numerous heterogeneous cell populations. Thus, both mitochondrial 
respiration and aerobic glycolysis contribute differently to each population and favor tumor growth 
and survival under different conditions. Cancer cells have flexible metabolic phenotypes. Under 
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nutrient/glucose-limited conditions, glycolytic cancer cells can  alter metabolism, via activation of 
signaling pathways and transcription factors, and restore partly suppressed OXPHOS20,21. Those 
cancer cells able to perform oxidative metabolism and particularly located in close proximity to 
blood vessels, can utilize energy-rich fuels (such as pyruvate, ketone bodies, fatty acids and lactate) 
produced by their neighboring cells (proliferating cancer cells and CAFs) to fuel mitochondrial 
OXPHOs for ATP production22. This utilization of lactate and other energy-rich fuels by cancer 
cells capable of using oxidative metabolism is referred to as the “Reverse Warburg effect”23.  
Tumor cancer cells affect their tumor microenvironment to maintain “Reverse Warburg effect”. 
For example, tumor cells have been shown to secrete hydrogen peroxide, which causes oxidative 
stress in neighboring CAFs. This induces aerobic glycolysis accompanied with high lactate 
production in CAFs, and the lactate in turn fuels OXPHOS in oxidative cancer cells24.  
 
V. Lactate Metabolism 
i. Lactate metabolism key players 
Highly glycolytic cancer cells produce high amounts of pyruvate that is converted into lactate by 
tetrameric isozymes called lactate dehydrogenases (LDHs). These isozymes are formed by the 
combination of two different subunits, LDHA and LDHB. The subunit LDHA has a higher affinity 
for pyruvate and a higher Vmax for pyruvate reduction than LDHB. As a result, the tetramer with 
more LDHA subunits catabolizes pyruvate to lactate and produces NAD+, which is essential for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in glycolysis. By contrast, tetramers rich in 
the LDHB isoform convert lactate to pyruvate, which allows cells to use lactate as a nutrient source 
for oxidative metabolism and/or for gluconeogenesis/reverse glycolysis. LDHB is ubiquitously 
expressed, especially in oxidative cardiac muscle, whereas LDHA is the predominant isoform 
found in Type II skeletal muscle fibers and other highly glycolytic tissues25.  
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Lactate levels within the extracellular tumor microenvironment are determined by the balance of 
lactate uptake and lactate export by tumor and tumor-associated cells. Lactate is transported across 
the plasma membrane of cancer cells through monocarboxylate transporters (MCTs). MCTs are 
proton-linked transporters and possess different affinities for lactate, which, in turn, partly 
determines the direction of lactate flux. Thus, secretion of lactate is through the low-affinity lactate 
transporter MCT4 (Km≈28 mmol/L) and lactate uptake primarily occurs through the high-affinity 
MCT1 transporter (Km≈1– 3.5 mmol/L)26. In normal physiology, MCT4 is highly expressed in 
glycolytic tissues like type IIB skeletal muscle fibers and astrocytes, whereas MCT1 is highly 
expressed in oxidative tissues, including cardiac muscle, Type I skeletal muscle fibers, and 
neurons. 
ii. Lactate as a nutrient source 
More than a waste product of glycolysis, lactate was recently identified as a major energy fuel for 
oxidative tumor cells.  Lactate, secreted by glycolytic tumor cells through the lactate exporter, 
MCT4, may be taken up by oxidative tumor cells through lactate importer MCT1, converted into 
pyruvate by LDHB and used as a fuel for oxidative metabolism27,28. Thus, oxidative tumor cells 
spare glucose which may, in turn, reach glycolytic tumor cells. This “lactate shuttle” is part of the 
metabolic symbiosis between tumor cells and it is an important component in the “Reverse 
Warburg effect” phenomenon described in different types of cancer including breast cancer 27–30. 
iii. Lactate signaling molecule 
Lactate plays a critical role in cancer progression and metastasis by promoting cancer cell 
migration, immune escape and angiogenesis 31–33. Extracellular lactate promotes tumor cell 
migration and angiogenesis by inducing the secretion of the cytokine IL-8 and the vascular 
endothelial growth factor (VEGF) by endothelial cells 31,34,35. Moreover, lactate is able to block 
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immune surveillance by inhibiting the differentiation of monocytes and natural killer cells33,36. 
Also, the secretion of lactate through MCTs releases H+, decreasing the extracellular pH that 
affects T-cell function and provokes local inflammation37,38. 
Recently two signaling pathways have been identified where lactate acts as a “signaling molecule” 
to promote angiogenesis and tumor growth. First, lactate inhibits prolylhydroxylase 2 (PHD2), the 
enzyme that hydroxylates HIF1α, inhibiting its ubiquitination and subsequent proteasomal 
degradation. Thus, lactate promotes angiogenesis and other HIF1α-related effects in the absence 
of hypoxia39. Second, lactate also inhibits the proteosomal degradation of the tumor promoter, N-
Myc Downstream Regulated Gene 3 (NDRG3), another target of PHD2. Also, lactate binds 
directly to NDRG3 activating the Raf-ERK pathway to promote angiogenesis and cell growth 
during hypoxia40.  
iv. GPR81 
G protein-coupled receptor-81 (GPR81) has been identified as the endogenous receptor for lactate. 
Lactate activates GPR81 with a EC50 value of 5 mM, which is within the physiologic 
concentration range (1 to 20 mmol/L) of lactate within breast tumors. Also known as Hydroxy 
Carboxylic Acid Receptor 1 (HCAR1), GPR81 is part of the HCAR family that consists of three 
highly homologous receptors; GPR81 (HCAR1), GPR109a (HCAR2) and GPR109b (HCAR3), 
which are regulated by the specific agonist, L-lactate, 3-hydroxybutyrate and 3-hydroxyoctanoate, 
respectively41. In normal cell types (e.g., adipocytes), GPR81 is coupled to Gi/q, and activation of 
the receptor by L-lactate results in decreased cellular levels of cAMP and increased cellular levels 
of Ca2+. This receptor has been mainly studied in adipocytes, in which extracellular lactate 
specifically activates GPR81 to decrease the cAMP production and ultimately reduce lipolysis42. 
GPR81 is receiving increasing attention in the cancer field as a result of its upregulated expression 
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in several types of cancers like pancreas, colon, liver, breast, lung and cervix which in many cases 
the correlates with tumor growth, chemoresistance and metastasis 43–46.  In particular, one recent 
study showed that GPR81 regulates lactate transporters MCT1 and MCT4 in pancreatic cancer 
cells and promotes cell growth/survival under nutrient stress conditions 44.  
 
VI. Significance 
Although, there is an increasing interest in the lactate metabolism of cancer, there are few 
studies on lactate metabolism in the context of metastatic transformation. Since EMT induces 
metastatic transformation, in chapter 3 we studied the metabolic reprogramming induced by EMT 
in breast cancer. We analyzed the alterations in the lactate metabolism of two epithelial breast 
cancer cell lines and their respective post-EMT mesenchymal breast cancer cell lines. In addition, 
we studied the role of the lactate importer MCT1 in the epithelial breast cancer cells.   
The lactate receptor GPR81 has been shown to promote cancer progression. In chapter 4, 
we studied the expression of GPR81 in human breast cancer tissues and in a EMT breast cellular 
model. We also studied the role of this receptor in epithelial breast cancer cells and its potential as 
a therapeutic target.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
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Cell culture 
BT-474 and MCF-7 cell lines were obtained from the American Type Culture Collection 
(Manassas, VA). EMT in MCF-7 and BT-747 cells was induced using prolonged mammosphere 
culture method as reported previously47,48. BT-474 and MCF-7 and their corresponding EMT-
derived BT-474-M and MCF-7-M cells were grown in DMEM/F-12 containing 10% heat 
inactivated FBS (Gibco, Grand Island, NY) and 1× MycoZap™ Plus-CL antibiotic 
(Lonza,Walkersville, MD). BT-474 and MCF-7 cells were additionally supplemented with 1× 
Insulin–Transferrin–Selenium solution (Gibco, Grand Island, NY). All cells were incubated at 5% 
CO2 and at 37 °C. 
Physiological modified medium and drugs 
RPMI 1640 Medium Modified without l-Glutamine, without Amino acids and Glucose (US 
Biological, Swampscott, MA) was supplemented with 5 mM D-glucose, 2.5 mM L-glutamine 
(Sigma, St. Louis, MO), 1× MEM essential and non-essential amino acid mixtures, 10% heat 
inactivated FBS, 15 mM HEPES (Gibco, Grand Island, NY); 0.5 mM sodium pyruvate, chemically 
defined lipid mixture 1, 15 mM sodium bicarbonate, 1 mM Na-lactate (Sigma, St. Louis, MO) and 
1× MycoZap™ Plus-CL antibiotic (Lonza,Walkersville, MD).  
RPMI-1640 Medium Modified with L-glutamine, without phenol red and sodium bicarbonate 
(Sigma, St. Louis, MO) was used in assays where cells were treated with β-Estradiol or Tamoxifen. 
MCT1 inhibitor SR 13800, β-Estradiol and Tamoxifen (Tocris Bioscience, Bristol, UK) solutions 
were made using ethanol and were used at concentrations of 100 nM, 10 nM and 1 µM, 
respectively. 
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3-dimensional culture  
Corning™ Matrigel™ GFR (Fisher Scientiic) or Matrigel™ (Corning) was used as culture matrix 
following a modified version of the previously described protocol for 3-dimensional on-top 
assay49. Twenty-four-well plates were coated with 200ul of the mix of 1:1 
Matrigel™/Physiological modified medium supplemented with 1x Insulin–Transferrin–Selenium 
solution (Gibco, Grand Island, NY) and kept at 37°C for 30 minutes to allow the Matrigel™ to 
solidify. All cell lines were suspended in physiological modified medium supplemented with 1x 
insulin and seeded into the coated twenty-four-plates. Epithelial and mesenchymal cells were 
seeded in 250µl at 100, 000 cells/well and 20, 000 cells/well, respectively, and incubated at 37°C 
for 30 minutes to allow cell attachment to the Matrigel. All wells were overlaid with 250µl of 
physiological modified medium containing 4% Matrigel™. Culture medium was replaced with 
fresh medium daily and cells were used for each assay after seven days, unless otherwise indicated. 
Imaging of 3-dimensional structures 
Cells were cultured in 3-dimensional Matrigel and glass bottom 24-well plate (MatTek 
Corporation, MA) for seven days. Phase contrast images of the 3-dimensional structures of 
epithelial and mesenchymal cells were imaged using a Zeiss Axio Observer inverted microscope 
(Carl Zeiss MicroImaging Inc., Thomwood, NY) equipped a QImaging Retiga EXi CCD digital 
camera (QImaging, Surrey, BC). For immunofluorescence images cell lines grown in 3-
dimensional Matrigel at the seventh day were fixed in 2% formaldehyde in 1X PBS for 20 minutes. 
Cells were washed with 1X PBS and then treated with 0.1% Triton-X 100 for 10 minutes. Cell 
were washed with 1X PBS and blocked with 1% bovine serum albumin (BSA) for 20 minutes. 
After blocking, cells were incubated with F-actin-staining phalloidin staining solution for 20 
minutes at room temperature. Phallotoxin staining solution was prepared with 5µl Alexa-488 
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Phallotoxin (Invitrogen, Carlsbad, CA) stock in 200µl 1X PBS for each well to be stained. 
SYTOXTM orange dye (Invitrogen, Carlsbad, CA) was used to stain nuclei. Images were captured 
using a Zeiss Pascal confocal system with a 40X 1.2 NA objective (Carl Zeiss Microscopy, 
Narashige, MN). 
Transient transfection of siRNA  
MCF-7 cells were seeded in 250ul at a density of 150, 000 cells/well in twenty-four-well plates 
coated with 200ul of the mix of 1:1 Matrigel™/Physiological modified medium supplemented 
with 1x Insulin–Transferrin–Selenium solution (Gibco, Grand Island, NY) and transiently 
transfected with Trilencer-27 human siRNA (siNT, siGPR81 “B” and siGATA3 “A”) at a final 
concentration of 10 nM (Origene, Rockville, MD) with Lipofectamine™ RNAiMAX transfection 
reagent (Thermo Scientific, Rockford, IL). After 8 hours of transfection cells were overlaid with 
250µl of physiological modified medium containing 4% Matrigel™. Culture medium was replaced 
with fresh medium every day and cells were used for each assay after 72 or 96 hours after 
transfection. 
Growth and viability assays 
For a seven-day growth curve, epithelial and mesenchymal cells were plated at a density of 
100,000 cells/well and 20,000 cells/well, respectively in 3-dimensional Matrigel™ culture. MCF-
7 cells were seeded at a density of 150, 000 cells/well for transient transfection and treatments with 
MCT1 inhibitor SR 13800 or Tamoxifen (Tocris Bioscience, Bristol, UK). Cells were recovered 
from Matrigel by incubating them with 5 mM EDTA (Gibco, Grand Island, NY) in ice cold 1x 
PBS for 30 minutes at 4°C and centrifuged for 5 minutes at 1000 rpm. Recovered cells were 
digested with 0.25% trypsin for 4 min and resuspended in DMEM with 10% FBS. The cell number 
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was calculated on hemocytometer at specific time point. Cell number viability assays were 
performed three times for each cell group.  
Real-time qPCR and primers 
Total RNA was isolated from cell lines using TRIzol Reagent (Ambion RNA, Carlsbad, CA), 
following the manufacturer’s instruction. cDNA was synthesized 1 μg of total RNA using 
iSCRIPT cDNA synthesis kit (Bio-Rad, Hercules, CA). SYBR green based SsoFast EvaGreen 
Supermix (Bio-Rad, Hercules, CA) was utilized to perform real-time PCR from 50ng of cDNA. 
Gene expression was normalized to TATA-box binding protein 1 (TBP1) using 2−ΔCt method. 
Specificity of the primer sets was confirmed by melting curve analysis. Primer sequences were 
listed in Appendix section.  
cDNA Arrays 
Real-time qPCR was performed in two TissueScan™ breast cancer and normal tissue cDNA arrays 
I and II (Origene, Rockville, MD). Gene expression was normalized to normal tissue using 2−ΔCt 
method. 
Real-time metabolic analysis 
Simultaneous multiparameter metabolic analysis of all four cell lines in culture was performed in 
the Seahorse XF96 extracellular flux analyzer (Seahorse Bioscience, Billerica, MA). Epithelial 
and mesenchymal cells were seeded in Seahorse 96-well XF cell culture microplate at 15,000 
cells/well and 8,000 cells/well, respectively, and pre-incubated at 37°C in 5% CO2. Following 48 
hours of incubation, the culture medium was replaced with assay media (unbuffered Seahorse XF 
Base medium supplemented with 5 mM D-glucose, 0.5 mM L-glutamine, 0.1 mM sodium pyruvate 
and 1 mM Na-lactate, pH 7.4) one hour before the assay in a non-CO2 incubator and for the 
duration of the experiment. Mitochondrial complex inhibitors (1 µM oligomycin, 1 μM FCCP, 0.5 
 
19 
 
μM rotenone) were preloaded in the injection ports. Three baseline measurements of oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) were made and were 
averaged to give the 100% starting value. After establishing the OCR and ECAR baselines, 
mitochondrial complex inhibitors (oligomycin, FCCP, rotenone) were injected consequently and 
after a short period of mixing, OCR and ECAR measurements were made using photodetectors 
with specific excitation and emission wavelengths of oxygen (532/650 nm) and protons (470/530 
nm; 28). These experiments were performed two times, each with ten samples per cell type. The 
data were normalized by cell number.  
Glucose uptake and lactate production 
Epithelial and mesenchymal cells were plated at a density 100,000 cells/well and 20, 000 cells/well 
in 3-dimensional Matrigel™ culture for seven days. For transient transfection, MCF-7 cells were 
seeded at a density of 150, 000 cells/well and medium was changed daily. Glucose and lactate 
concentrations in the culture medium were determined by fluorometric-based Glucose Assay Kit 
and Lactate Assay Kit (BioVision, Inc., Milpitas, CA) according to the vendor’s instructions using 
Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT). The amount consumed or 
produced by cells was determined by comparing the concentration in the medium incubated 
without cells and then normalized to cell number. These assays were performed three times with 
two experimental replicates for each cell group. 
Western blot and antibodies 
Cells were collected form 3-dimensiona Matrigel™ culture (as described previously) and lysed 
with RIPA buffer (TEKnova, Hollister, CA) containing Halt Protease and Phosphatase Inhibitor 
Cocktail (Thermo Scientific, Rockford, IL). The lysates were clarified by centrifugation at 4 °C 
for 10 min at 12,000 ×g. The concentration of protein in the supernatants was measured using BCA 
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assay (Thermo Scientific Pierce, Rockford, IL). Total proteins (20 μg/lane) were separated on a 
10% SDS-PAGE and were transferred to nitrocellulose membrane. The membranes were blocked 
with 5% BSA in 1× TBST (β-actin, LDHA and LDHB) or with 5% non-fat milk (MCT1, MCT4 
and Cleaved PARP) and subsequently incubated with primary and secondary antibodies according 
to the vendor’s instructions. Blots were visualized by using Amersham ECL prime (GE Healthcare 
Life Sciences, Buckinghamshire, UK) and imaged using G:box imaging system (SynGene, 
Cambridge, UK). Primary antibodies to LDHA (1:10,000) was purchased from Cell Signaling 
Technology (Danvers, MA); Cleaved PARP (1:1000 from Cell Signaling Technology (Danvers, 
MA) was a gift by Dr. K. Claffey, Dept of Cell Biology and Center for Vascular Biology, UConn 
Health); β-actin (1:2500) and MCT1 (1:1000) were purchased from Abcam (Cambridge, MA); 
LDHB (1: 10,000) was purchased from OriGene (Rockville, MD). MCT4 (1:1000) was purchased 
from Millipore (Billerica, MA). All images were imported to Image J for pixel grayscale intensity 
analysis. Western blot analysis was performed three times using two independent protein samples 
for each cell group. 
Nuclear Magnetic Resonance (NMR) Spectroscopy and Data Analysis 
Cells were collected form 3-dimensional Matrigel™ culture (as described previously) and lysed 
with 1:1:1 methanol/chloroform/water in sequence with 5 seconds of gyration between additions. 
In order to optimize chemical extraction, non-trypsin-based methods were employed as follows50. 
A 10 µL sample was then removed for cell counting. Resulting lysed solution was then allowed to 
separate overnight at 4°C to form resultant aqueous and organic layers. Aqueous layer containing 
metabolites of concern were then manually extracted and resulting solution was subjected to 
addition of Chelex (approx. 3mg/mL) for removal of divalent ions, which was then removed 
through vacuum filtration using Buchner filter. Solution was then lyophilized overnight to form 
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solid components. 800 µL of D2O with 10 mM EDTA and 1 mM 4,4-dimethyl-4-silapentane-1-
sulfonic acid (DSS) was added and solution was centrifuged at 3000RPM for 5 minutes prior to 
placement in standard 5 mm NMR tube for 1H NMR. 
1H NMR experiments were performed on 500 MHz Agilent spectrometer with HCN cold probe 
and a VNMRS console. Default pre-saturation pulse sequences were utilized with the following 
parameters: pulse-width = 7.2 µs, sweep-width = 8389.26 Hz, 2460 complex points, D1 = 1.5 s, 
SATPWR = 6 dB on H2O signal, and 64 transients. Resulting 
1H NMR underwent Fourier 
Transformation and data was further analyzed in MestReNova NMR software, version 9.0.0. 
Processing template for all spectra had the following time domain corrections: drift correction to 
tail points of 5% and apodization through an exponential of 1.5 Hz. The frequency domain had 
global phase correction and a baseline correction using Bernstein polynomial of n=3. Reference 
signal was set as the singlet produced off of DSS at 0 ppm. Lactate and Pyruvate were identified 
on the spectra through prior titration analyses and the absolute area under the curve was used for 
their methyl groups with respect to methyl groups found off of DSS with the usage of Line-Shape 
analysis. These areas were used to calculate concentrations by a ratio of the absolute area to the 
number of protons in the signal used. Resulting concentrations in millimolar were then exported 
into an Excel spread sheet containing cellular counts to determine a normalized concentration per 
number of cells.  
Statistical analysis 
Ordinary one-way ANOVA followed by Sidak’s multiple comparison post-test or two-way 
ANOVA was performed to determine statistical significance. P < 0.05 was considered to be 
significant. Statistical analysis was performed using GraphPad Prism software (La Jolla, CA). 
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CHAPTER 3 
 
EPITHELIAL-MESENCHYMAL TRANSITION INDUCES CHANGES IN THE 
LACTATE METABOLISM OF BREAST CANCER CELL LINES 
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I. Abstract  
Lactate is both a metabolite of glycolysis and a component of several signaling pathways. 
Although recent studies indicate that lactate is a critical regulator of cancer development, very 
little is known about lactate metabolism in the context of metastatic cancer. Epithelial-
mesenchymal transition (EMT) promotes metastasis by inducing invasive properties in epithelial 
tumors. To determine whether EMT induces metabolic alterations, we have studied two epithelial 
breast cancer cell lines (MCF-7 and BT-474) and their respective EMT-induced mesenchymal 
progeny (MCF-7 M and BT-474 M) for changes in lactate metabolism. Metabolic analysis 
revealed that EMT induced an enhanced glycolytic profile in mesenchymal breast cancer cells 
along with the overexpression of glucose transporters (GLUT3, GLUT12), lactate dehydrogenases 
(LDHA, LDHB) and monocarboxylate transporter 4 (MCT4). In contrast, epithelial breast cancer 
cells preferentially used oxidative phosphorylation (OXPHOS) to produce ATP.  These aerobic 
epithelial breast cancer cells highly expressed the estrogen receptor α (ERα) and the 
monocarboxylate transporter 1 (MCT1). We found that the epithelial breast cancer cells but not 
the mesenchymal breast cancer cells imported lactate through MCT1 and used it as an alternative 
nutrient to support cell growth. The strong expression of MCT1 in epithelial breast cancer cells 
was regulated by ERα signaling pathway and the transcription factor GATA3. In addition, the co-
treatment of epithelial breast cancer cells with Tamoxifen and MCT1 inhibitor inhibited cell 
proliferation to a significantly greater extent than with either drug by itself. Our study suggests the 
potential of MCT1 as a therapeutic target to treat ER-positive epithelial breast cancer.   
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II. Introduction   
Invasive breast cancer (IBC) is the predominant form of cancer among women worldwide and the 
second cause of cancer-related deaths in women in the United States51 5. The most common type 
of IBC, called Luminal A, is characterized by an adhesive epithelial phenotype and overexpression 
of the estrogen receptor α (ERα). Although Luminal A IBC is a relatively indolent, non-aggressive 
form of cancer, failure of early detection is significantly associated with metastatic disease, which 
in turn is responsible for the majority of deaths in breast cancer patients.  
Metastatic dissemination of IBC involves a succession of complex events that ultimately 
lead to the colonization of distant organs52. Either complete or partial epithelial-mesenchymal 
transition (EMT) has been implicated in the earliest stages of metastasis8. EMT allows for the 
detachment of cells from the main tumor mass, and increases motility and invasiveness of tumor 
cells, coupled to increased autonomous production of extracellular matrix. Differing degrees 
and/or modes of EMT are orchestrated by a range of transcriptional and epigenetic mechanisms 
among the heterogeneous population of cells within a tumor. The process of EMT can be induced 
by exposure of cancer cells to an altered microenvironment (e.g., hypoxia, increased cytokines) 
that is imposed by the tumor itself (or a subpopulation thereof), by surrounding cells (e.g. 
macrophages) in response to a growing tumor, and/or by systemic physiology that has been altered 
(e.g., by obesity). Additional somatic mutations in highly proliferative cells also likely contribute 
to a changing microenvironment and/or the responsiveness of tumor cells to the microenvironment 
10 12.  
Cancer cells frequently exhibit increased glucose uptake, glycolytic rates and lactate 
production in the presence of oxygen, a process referred to as “aerobic glycolysis” or “Warburg 
effect” 16. A large body of recent studies revealed that aerobic glycolysis and other metabolic 
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changes allow cancer cells to accumulate building blocks for the biosynthesis of macromolecules 
that are used in anabolic pathways, while simultaneously satisfying the high energy demands and 
maintaining redox balance needed for cell proliferation53. These metabolic changes are collectively 
referred to as “metabolic reprogramming”, now considered a hallmark of cancer cell biology14,54. 
Most studies on metabolic reprogramming have been performed in the context of transformation 
per se, i.e., the comparison of metabolic pathways in non-neoplastic cells to those in their 
neoplastic counterparts55–57. More recent studies have also demonstrated that metabolic 
reprogramming occurs within epithelial cancer cells that partially or completely transition to 
mesenchymal cancer cells. Some studies have indicated that metabolic reprograming contributes 
to the acquisition and maintenance of the mesenchymal phenotype in breast cancer cells and this 
cell type exhibits a specific metabolic signature associated with poor clinical outcome in breast 
cancer patients 58,59. 
We previously reported that prolonged 3-dimensional mammosphere culture induced EMT 
in two distinct epithelial breast cancer cell lines, MCF-7 and BT-474 cells, generating stable 
populations of mesenchymal cancer cells, termed MCF-7M and BT-474M cells, respectively47,48. 
Using standard 2-dimensional culture on plastic dishes and a standard tissue culture medium 
(DMEM/F12) containing supra-physiological levels of several nutrients (especially glucose), we 
characterized these four cell lines with respect to metabolism by assaying the expression of 
enzymes and specific metabolite transporters associated glycolysis and associated side-pathways, 
and in terms of glucose uptake and lactate production. These analyses indicated that both epithelial 
MCF-7 and BT-474 cells are less glycolytic than the two mesenchymal MCF-7M and BT-474M 
cell lines, but express higher levels of enzymes involved in reverse glycolysis and certain 
glycolytic side-pathways. In the current study, we directly examined the degree of oxidative vs 
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glycolytic metabolism in these 4 cell lines, using a culture system that involves both a 3-
dimensional Matrigel matrix and media containing the physiological levels of glucose (5 mM), 
lactate (1 mM), glutamine (0.5 mM) and pyruvate (0.1 mM). In addition, we further examined 
metabolic differences in lactate flux and utilization in these phenotypically different cell lines. 
Finally, we showed that MCT1 is required for lactate import and survival of the epithelial, but not 
mesenchymal, breast cancer cells. 
 
III. Results 
Epithelial And Mesenchymal Phenotypes In 3-Dimensional Culture 
A major objective of this study was the characterization of aspects of metabolism in the 
two epithelial MCF-7 and BT-474 cell lines and the corresponding post-EMT mesenchymal MCF-
7M and BT-474M progeny within a culture system that was more physiologically-relevant and in 
which specific nutrients were better defined. Thus, the four cell lines were cultured within a 3-
dimensional Matrigel configuration as described by Bissell and colleagues49. In addition, the 
culture medium contained physiological levels of glucose (5 mM), lactate (1 mM), glutamine (0.5 
mM) and pyruvate (0.1 mM), with medium changed daily, unless noted otherwise. Note that media 
was supplemented with 10% FBS, so that final concentrations of these nutrients was moderately 
higher than the values stated above. Note also that medium was changed daily as opposed to being 
constantly perfused, so that the levels of these nutrients were subphysiological by the 23rd hour. 
Under these conditions (termed MPM culture, for Matrigel & Physiological Medium), both 
epithelial cell lines grew as tightly adherent spheroids for 1 week (Figure 3.1. A; “E” boxes). The 
two mesenchymal cell lines also formed tight spheroids initially, but after 2 days began invading 
the Matrigel (Figure 3.1. A; “M” boxes).  
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After 1 week of MPM culture, cells were examined for the expression of specific epithelial, 
mesenchymal, EMT-related and stem cell-like markers. Epithelial spheroids maintained a high 
level of expression of the epithelial zonula adherent protein, E-cadherin, and the Luminal A-related 
transcription factor, GATA3 (Figure 3.1 B). Epithelial cells also expressed relatively high levels 
of the hormone receptors, ERα, PR and/or HER2 (Figure 3.1 B). In contrast, mesenchymal cells 
showed no or very low expression of E-cadherin, GATA3 and the three hormone receptors. 
Mesenchymal cells expressed high levels of the mesenchymal marker, Vimentin, along with EMT-
related transcription factors, Zeb 1 and Zeb 2 (Figure 3.1. B). Finally, the two epithelial cell lines 
displayed high CD24 but low CD44 expression consistent with a mammary cell differentiated 
phenotype, whereas the two mesenchymal cell lines displayed high CD44 expression and low 
CD24 expression, consistent with a less differentiated, “breast cancer stem cell” phenotype (Figure 
3.1. B). The mesenchymal cells also expressed a mammary stem cell phenotype with high 
expression of integrin α6 (CD49f) and the loss of the proto-oncogene c-Kit expression60–62 (Figure 
1B).  Both mesenchymal MCF-7M and BT-474M cell lines had a higher rate of proliferation, along 
with elevated expression of mRNAs encoding cyclin B1 and Ki67 (Figure 3.2. A-B). These data 
are consistent with our previous findings in these cells, both in 2-dimensional cell culture and after 
orthotopic transplantation into mice47,48. 
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Figure 3.1. Epithelial MCF-7 and BT-474 and mesenchymal MCF-7M and BT-474M breast 
cancer cells in 3-dimensional Matrigel culture.  
Top: phase contrast images of epithelial (E) and mesenchymal (M) cells in 3-dimensional Matrigel 
with physiological modified medium (MPM) for 7 days. Bottom: fluorescence microscopy images 
of 3-dimensional structures of epithelial and mesenchymal cells. Green: phalloidin staining of F-
actin. Red: nuclei counterstained with SYTOXTM orange nucleic acid. Scale bar, 10μm. B. Real-
time qPCR analysis of epithelial markers, E-cadherin and GATA3; mesenchymal marker, 
vimentin; hormone/growth factor receptors, ER, PR and HER2; EMT transcription factors, ZEB1 
and ZEB2; breast cancer and mammary epithelial stem cell markers, CD24, CD44, CD49f and c-
Kit in BT-474, BT-474M, MCF-7and MCF-7M cells. Results are presented as mean ± S.E.M. from 
three independent experiments (n>6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(ordinary one-way ANOVA). 
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Figure 3.2. EMT-induced mesenchymal MCF-7M and BT-474M breast cancer cells 
exhibited high cell proliferation rate in 3-dimensional Matrigel culture.  
A.  Increase in viable cell counts for epithelial (E) and mesenchymal (M) breast cancer cells at 
days 3, 5 and 7 of culture after subtracting the initial cell number. B. Real-time qPCR analysis of 
proliferation markers: cyclin B1 and Ki67. Results are presented as mean ± S.E.M. from three 
independent experiments (n=6) *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA). 
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Epithelial MCF-7 And BT-474 Breast Cancer Cells Are More Oxidative, Whereas Post-EMT 
Mesenchymal MCF-7M And BT-474M Breast Cancer Cells Are More Glycolytic 
Subsequent studies investigated whether metabolic reprogramming is linked to EMT as 
assessed in breast cancer cells culture in physiological medium. Energy metabolism in the two 
epithelial MCF-7 and BT-474 cell lines and the two post-EMT mesenchymal MCF-7M and BT-
474M cell lines was examined in real time by the assay of oxygen consumption rate (OCR; a 
measure of mitochondrial oxidative phosphorylation), extracellular acidification rate (ECAR; a 
measure of glycolysis linked to the export of lactate anions and protons) and the dependency on 
mitochondrial respiration for ATP production (see Chapter 2 Methods & Materials). Epithelial 
cancer cells exhibited robust basal OCR but a low ECAR, whereas mesenchymal cells consumed 
oxygen at a lower rate and showed a significantly higher ECAR (Figure 3.3. A). We further 
explored mitochondrial function between epithelial and mesenchymal breast cancer cells by 
determination of ATP-coupled respiration and maximal respiration capacity. Epithelial cancer 
cells showed significantly higher mitochondrial ATP production and a greater maximal respiratory 
capacity than mesenchymal cancer cells (Figure 3.3. B). Thus, the metabolism of both post-EMT 
mesenchymal cell lines was shifted more towards aerobic glycolysis.  
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Figure 3.3. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer cells 
exhibited a more glycolytic profile compared to their parental epithelial MCF-7 and BT-474.  
Epithelial (E) and mesenchymal (M) cells were seeded on a Cell-Tak-treated XF24 cell culture 
plate. Data were obtained with the XF Extracellular Flux Analyzer (Seahorse Bioscience). A. 
Metabolic phenotype plot of basal oxygen consumption rate (OCR) vs. basal extracellular 
acidification rate (ECAR) measurements. B. Schematic representation of the mitochondrial 
function assay. After establishment of baseline OCR, sequential injection of oligomycin (ATP 
synthase inhibitor), FCCP (mitochondrial uncoupler) and rotenone plus antimycin A (complex I 
and III inhibitors, respectively) allowed for the determination of ATP-linked Respiration and 
Maximal Respiratory Capacity. Results are presented as mean ± S.E.M. of two different 
experiments (n=16) *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA). 
 
 
33 
 
 
Efficient Glycolysis and Lactate Export By Mesenchymal Cells 
Consistent with a more glycolytic phenotype, both MCF-7M and BT-474M mesenchymal 
cells displayed elevated glucose uptake (Figure 3.4. A), along with elevated expression of mRNAs 
encoding GLUT3 and GLUT12, in addition to robust expression of GLUT1 mRNA observed in 
all 4 cell lines (Supplemental figure 3.1. A). Aerobic glycolysis is associated with the reduction 
of pyruvate to lactate anion coupled to the oxidation of NADH to NAD+ by lactate dehydrogenase 
A (LDHA)-rich tetramers. The lactate anion and a proton undergo co-transport out of the cell 
through the monocarboxylate transporters (MCTs; primarily MCT4). The mesenchymal MCF-7M 
and BT-474M cells exported higher levels of lactate than the epithelial cells (Figure 3.4. B), and 
expressed high levels of MCT4 mRNA and protein (Figure 3.4. C-D). Both LDHA and LDHB 
protein expression were elevated in the mesenchymal MCF-7M and BT-474M cell lines (Figure 
3.4. E-F). NMR analysis revealed that the steady-state levels of intracellular pyruvate and lactate 
were very low in the two mesenchymal cell lines under MPM conditions (Figure 3.4. G-I). 
Together, these findings demonstrate that both of the post-EMT mesenchymal cell lines rely more 
heavily on the rapid metabolism of glucose through glycolysis, followed by efficient conversion 
of pyruvate to lactate and the export of lactate. 
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Figure 3.4. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer cells 
exhibited increased lactate production along with upregulation of lactate dehydrogenases 
and downregulation of specific lactate transporter.  
A-B. Glucose consumption and lactate production rates of epithelial (E) and mesenchymal (M) 
breast cancer cells. Real-time qPCR analysis and protein expression of C-D. lactate transporters: 
MCT1 and MCT4; E-F. lactate dehydrogenases: LDHA and LDHB in epithelial (E) and 
mesenchymal (M) breast cancer cells cultured in 3-dimensional Matrigel with physiological 
modified medium for 7 days. β-actin was used as a loading control. G. NMR profile of lactate 
doublet, 1.31 ppm, 1.32ppm. pyruvate profile: singlet, 2.37 ppm. H-I. Intracellular lactate and 
intracellular pyruvate of epithelial (E) and mesenchymal (M) breast cancer cells cultured in 3-
dimensional Matrigel for 7 days using NMR analysis. The bars represent the mean ± S.E.M. of 
three independent experiments; (n>4) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(ordinary one-way ANOVA). 
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Lactate As A Potential Nutrient In Epithelial Cells 
Both epithelial cell lines also exported lactate under MPM culture conditions, albeit at a 
significantly lower rate than the mesenchymal cells (Figure 3.4. B). In contrast to the 
mesenchymal cell lines, both epithelial cell lines expressed the lactate and pyruvate transporter, 
MCT1, at relatively high levels, but expressed the lactate exporter, MCT-4, at very low levels 
(Figure 3.4. C-D). Additionally, NMR analysis indicated higher intracellular pools of pyruvate 
and lactate in both epithelial cell lines (Figure 3.4. G-I). Thus, the two epithelial cell lines maintain 
an accessible pool of pyruvate for mitochondrial respiration and an accessible pool of lactate that 
could be converted to pyruvate if needed. As stated above, although the LDHB mRNA levels are 
low in both epithelial cell lines, LDHA and LDHB protein levels were readily detectable by 
immunoblot (Figure 3.4. E-F), indicating some capacity for the interconversion of pyruvate and 
lactate. 
The findings above indicated that lactate, as provided through MCT1, can potentially be 
used as a fuel by the two epithelial cell breast cancer lines. We therefore examined whether MCT1 
function promoted cell growth in epithelial cell lines that display robust MCT1 expression (Figure 
3.4. C-D). Treatment of cells with the potent MCT1 inhibitor SR13800, slowed the growth of both 
epithelial cell lines, but had no effect on the mesenchymal cells, in the presence of physiological 
levels of glucose, lactate, glutamine and pyruvate (Figure 3.5. A-B). In the presence of 0.1 mM, 
1 mM or 10 mM lactate but without glucose, glutamine and pyruvate, epithelial cell growth was 
moderate, but nevertheless was positively correlated with increasing extracellular lactate, and this 
effect of lactate on cell proliferation was blocked by the MCT1 inhibitor (Figure 3.5. C-D). 
Increasing extracellular lactate had no effect on mesenchymal cells (Supplemental figure 3.2.). 
These data show a differential ability of epithelial breast cancer cells to import lactate for growth. 
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Figure 3.5. MCT1 inhibitor treatment reduced the cell proliferation of epithelial MCF-7 and 
BT-474 breast cancer cells in normal and nutrient-limited conditions.  
Viable cell counts under the following conditions: A-B. Epithelial (E) and mesenchymal (M) cells 
were cultured in 3-dimensional Matrigel with 100 mM MCT1 inhibitor SR 13800 for 4 days. C-
D. Epithelial MCF-7 and BT-474 cell lines were cultured in 3-dimensional Matrigel with 
physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM 
concentrations for 4 days and treated with or without MCT1 inhibitor SR 13800. Results are 
presented as mean ± S.E.M. of three independent experiments; (n=6) *p < 0.05; **p < 0.01; ***p 
< 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
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GATA3 Expression Promotes MCT1 Expression 
The UCSC Genome Browser shows an H3K27Ac mark coinciding with a DNase-
hypersensitive region about 5 kb upstream of the human MCT1 transcription start site. Analysis 
of this region revealed that it harbors a GATA3 binding site (Figure 3.6. A). The transcription 
factor, GATA binding protein 3 (GATA3), is essential for proper mammary development and has 
strong association with the expression of the estrogen receptor (ERα) in breast cancer63,64. We 
observed that GATA3 knockdown significantly decreased MCT1 and ERα relative expression, but 
had no effect on MCT4 (Figure 3.6. B).  
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Fig. 6. GATA3 Expression Promotes MCT1 Expression 
 A. GATA3 binding site in the DNase-hypersensitive region of the human MCT1 gene (UCSC 
Genome Browser; ORegAnno Regulatory Site Database65) B. Relative mRNA expression of 
transcription factor GATA3, lactate transporters MCT1 and MCT4, and estrogen receptor α (ERα) 
in MCF-7-Mock, MCF-7-siNT and MC-7-siGATA3 for 96 hours in MPM culture. Results are 
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presented as mean ± S.E.M. of three different experiments (n=6) *p < 0.05; **p < 0.01; ***p < 
0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
ERα signaling regulates MCT1 expression 
The higher expression of MCT1 in ERα-positive epithelial cells raises the possibility that either 
ERα directly stimulates MCT1 gene transcription, or that ERα/luminal-related transcription factors 
(e.g., GATA3, FOXA166,67) stimulate MCT1 expression. Indeed, treatment of both epithelial 
MCF7 and BT474 cell lines with 10 nM E2 or 1 M Tamoxifen in MPM containing some 
estrogenic activity (phenol-red, 10% FBS) showed that Tamoxifen significantly suppressed the 
expression of MCT1 and progesterone receptor (positive control). MCT4 expression was 
unchanged by either E2 or Tamoxifen, demonstrating a selective action on MCT1 expression 
(Figure 3.7. A). This raised the possibility that Tamoxifen may suppress breast cancer cell 
proliferation, in part, by lowering expression of MCT1, and that the combination adjuvant therapy 
with both Tamoxifen and an MCT1 inhibitor may impose a more complete inhibition of growth 
and viability in ERα-positive breast cancers. Co-treatment of epithelial MCF-7 and BT-474 cells 
with MCT1 inhibitor SR13800 and Tamoxifen inhibited proliferation to a significantly greater 
extent than with either drug by itself (Figure 3.7. B) but not mesenchymal breast cancer cells 
(Supplemental figure 3.3. C).  
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Figure 3.7. ERα signaling regulates MCT1 expression 
A. Relative mRNA expression of lactate transporters: MCT1 and MCT4; and progesterone 
receptor (PR) of epithelial (E) and mesenchymal (M) breast cancer cells in 3-dimensional Matrigel 
culture and treated with 10 nM β-estradiol (E2) or 1 µM Tamoxifen (TAM) for 4 days. B. Viable 
cell counts of epithelial MCF-7 and BT-474 breast cancer cells in 3-dimensional Matrigel culture 
and treated with 1 µM Tamoxifen (TAM) +/- 100 mM MCT1 inhibitor SR 13800 for 4 days. 
Results are presented as mean ± S.E.M. of three different experiments (n=6) *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
IV. Discussion 
The behavior and progression of breast cancer is strongly influenced by the tumor 
microenvironment, which includes the extracellular matrix and the levels of extracellular nutrients. 
The matrix that surrounds cells in a 3-dimensional field impacts the configuration of the cell, 
regulates the concentrations of nutrients, exported metabolites and H+ ions, allows cells to 
generate motile and stress forces, and modulates intracellular signaling pathways14,68,69. 
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Extracellular fuels, specifically glucose, lactate, glutamine and pyruvate, contribute to the levels 
of intracellular metabolites, many of which impose allosteric regulation on metabolic pathways 
28,70,71and enable anabolic pathways required for cell proliferation. For example, Elia et al recently 
demonstrated that 3D culture of Ras-transformed MCF10A mammary epithelial cells in soft agar 
induced a shift towards proline metabolism, and that cells in 3D culture also imported proline, 
whereas cell in 2D culture exported proline72.     
Therefore, we revisited and extended our previous studies on EMT and metabolic 
reprogramming47 by adapting a 3-dimensional culture method in Matrigel, and using a modified 
culture medium with 4 major nutrients at approximately physiological concentrations 
(“Matrigel/physiological medium” or “MPM”). In MPM culture, the two epithelial and two 
derivative mesenchymal cell lines displayed marked morphological differences and 
motility/invasiveness that is difficult to perceive in a constrained ‘flat’ plain of the traditional 2-
dimensional plastic culture. In addition to increased invasiveness within the Matrigel, the two post-
EMT mesenchymal cell lines displayed a triple-negative phenotype with increased proliferation, 
and expressed EMT-related and stem cell-related markers under MPM culture conditions.  
Previous studies on metabolic reprogramming in the context of metastatic transformation 
or EMT suggest that this process facilitates the metabolic shift toward glycolysis. For example, 
the EMT-related transcription factor, SNAIL, mediates the suppression of mitochondrial 
respiration through the Wnt/Snail signaling pathway, and enhances glycolysis by silencing the 
gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) in breast cancer58,73. In a previous 
study, we reported that the two mesenchymal cell lines, MCF-7EMT and BT-474EMT underwent an 
apparent glycolytic shift, as evidenced by enzyme and transporter expression, glucose uptake, 
lactate production and relative sensitivities to several metabolic inhibitors47.  
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In the present study, we observed that EMT-induced cancer cells had increased glucose 
uptake and lactate production when cultured in 3-dimensional MPM. We also examined in real 
time the metabolic changes induced by EMT using the Seahorse extracellular flux technology in 
all four cell lines and in physiological modified medium. The significantly lower levels of OCR in 
the EMT-induced mesenchymal breast cancer cells were accompanied by an increase in ECAR 
levels when compared to the parental epithelial cell lines, confirming a glycolytic shift in the 
mesenchymal cell lines. 
Acidification of the extracellular fluid (i.e., an enhanced ECAR) is generated primarily by 
the co-export of lactate anion and a proton. Lactate is generated from pyruvate, the end product of 
glycolysis, by lactate dehydrogenase isoform A (LDHA) -enriched tetramers. This reaction also 
oxidizes NADH to NAD+ that is essential for the continuation of a high glycolytic flux. Tetramers 
enriched in LDHB catalyze the reverse reaction of lactate to pyruvate. We observed increased 
protein levels of both LDHA and LDHB in the two mesenchymal cell lines. LDHA overexpression 
is a hallmark of many types of cancer, the majority of which are highly glycolytic, and elevated 
levels of LDHA connotes poor prognosis in pancreatic, squamous head and neck, gastric and breast 
cancer55,74–76. In contrast, the association of LDHB with breast cancer is more complex. LDHB, 
which converts lactate to pyruvate, was shown to be silenced by promoter methylation in breast 
cancer cells under hypoxia to enhance glycolysis77. However, one study associated high levels of 
LDHB with a more glycolytic and basal-like phenotype among several breast cancer cells 77. 
Moreover, another study showed that LDHB was highly expressed in triple-negative breast cancer 
as compared with other subtypes of breast cancer and patients with elevated LDHB experienced 
poor clinical outcome 78. Further studies are needed to examine whether the LDH isoforms are 
modified in cancer cells in a manner that confers either different enzymatic actions with respect to 
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pyruvate and lactate, or entirely new actions that are unrelated to the interconversion of these two 
metabolites. 
The co-export of lactate and a proton is accomplished by specific isoforms of the 
monocarboxylate transporter (MCT) family79. While the release of lactate occurs through the low-
affinity lactate transporter MCT4 (Km≈28 mmol/L), the import of lactate occurs through the high-
affinity MCT1 transporter (Km≈1– 3.5 mmol/L). In normal physiology, MCT4 is expressed in 
highly glycolytic tissues like type II skeletal muscle fibers and astrocytes and MCT1 is highly 
expressed highly oxidative tissues such as cardiac muscle, type I skeletal muscle fibers, and 
neurons 26,79. In our study, we observed that both EMT-induced mesenchymal cell lines displayed 
increased levels of the MCT4 transporter, and diminished levels of MCT1. The relative expression 
of MCT isoforms in relation to different types of breast cancer is not straight forward. Doyen et al 
reported that the expression of MCT4 was higher in TNBC compared to normal breast tissues 80 
and supports the correlation of elevated expression of MCT4 in the triple-negative mesenchymal 
cancer cells. In contrast, other studies have demonstrated a strong association of high expression 
of MCT1 with triple-negative breast cancer compared to other breast cancer types 81,82. However, 
one study reported that only 26% of their 31 TNBC samples showed high expression of MCT1 78. 
Interestingly, a recent report showed that MCT1 and MCT4 were co-expressed in some breast 
cancer tumors and cell lines 83. One possible explanation for these discrepancies is the plasticity 
of tumor cells to adapt to different tumor microenvironments. For example, the relative degree of 
vascularization and oxygen saturation in individual samples are typically not reported in studies 
of differential gene expression among different breast cancer types. 
We observed lower steady state levels of intracellular pyruvate and lactate in the 
mesenchymal cells, which, coupled to the findings of elevated glucose uptake, increased LDH and 
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MCT4 expression and increased lactate secretion, indicates that glycolytic cells are extremely 
efficient at lactate production and removal. Interestingly, lactate secreted by more glycolytic tumor 
cells, has been identified as a major energy fuel in tumors. Lactate is taken up by oxygenated tumor 
cells which use it to fuel oxidative metabolism27,84. Thus, oxidative tumor cells spare glucose 
which may, in turn, reach glycolytic tumor cells. This “lactate shuttle” between tumor cells has 
been described in different types of cancer including breast cancer 28. 
In contrast to the two EMT-induced mesenchymal cell lines, the two parental epithelial cell 
lines displayed a higher OCR but a lower ECAR. Further, the epithelial cells contained 
significantly more intracellular pyruvate and lactate. The epithelial cells expressed robust levels 
of MCT1 protein but very low levels of MCT4, and readily detectable levels of both LDH isoforms. 
These findings indicate that epithelial cells import lactate, convert lactate to pyruvate and maintain 
a reservoir of both metabolites to be used to maintain mitochondrial oxidative metabolism.  Our 
previous study47 and the findings shown in Supplemental Fig 1 indicate that epithelial cells express 
enzymes that can redirect carbons in pyruvate through reverse glycolysis and into anabolic and 
antioxidant pathways. Thus, MCT1-mediated lactate uptake also likely subserves the ability of 
epithelial cells to double their mass for proliferation. 
Lactate also functions independently of providing a carbon source, in that elevated levels 
of intracellular lactate may also regulate intracellular signaling pathways in epithelial cells85. For 
example, in oxidative cancer cells, lactate has been linked to activation of a “pseudo-hypoxic” Hif-
associated signaling, leading to activation of the c-myc signaling pathway, ultimately leading to 
an increase in glutamine uptake and metabolism39. Given the complexity of lactate actions, the 
MCT1 inhibitor likely decreases the viable cell number for the two epithelial cell lines through 
perturbation of multiple pathways. Further studies are needed to examine whether and how the 
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higher level of intracellular lactate in the two epithelial cells impacts signaling pathways that 
regulate other metabolic pathways, as this information may allow for higher precision in the 
inhibition of lactate intake and function to impair cancer cell metabolism (and lead to cell death) 
without allowing metabolic adjustments to override the impairments.  
Consistent with the fact that MCT1 mRNA and protein expression is significantly higher in ERα-
positive epithelial cells, Tamoxifen suppresses MCT1 expression. The combination of Tamoxifen 
and an MCT1 inhibitor had an additive effect on the decline in cell number in the two epithelial 
cell lines.  Also consistent with expression and function of MCT1 in epithelial Luminal A breast 
cancer cells, GATA3 also selectively stimulates MCT1 expression. Further studies are needed to 
better exploit this interaction of luminal transcription factors, ERα and GATA3, with MCT1 and 
lactate metabolism for therapeutic targeting of Luminal A breast cancer cells. 
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V. Supplemental figures 
 
 
Supplemental figure 3.1. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer 
cells showed upregulation of glucose transporters and downregulation gluconeogenic 
enzymes.  
Real-time qPCR analysis of A. glucose transporters; GLUT1, GLUT3 and GLUT12. B. lactate 
transporter; MCT2. C. gluconeogenic enzymes; PCK2, FBP1 and G6PD. Results are presented as 
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mean ± S.E.M. of three independent experiments (n>6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p 
< 0.0001 (ordinary one-way ANOVA). 
 
 
Supplemental figure 3.2. Cell proliferation of the EMT-induced mesenchymal MCF-7M and 
BT-474M breast cancer cells culture in 3-dimensional Matrigel and nutrient-limited 
medium.  
A. Mesenchymal MCF-7 M and BT-474 M cell lines were cultured in 3-dimensional Matrigel with 
physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM 
concentrations for 4 days. Results are presented as mean ± S.E.M. of three different experiments 
(n=6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
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Supplemental figure 3.3. Tamoxifen and MCT1 inhibitor treatment does not affect the cell 
proliferation of the EMT-induced mesenchymal MCF-7M and BT-474M breast cancer cells.  
A. Relative mRNA expression of lactate transporters; MCT2 of epithelial (E) and mesenchymal 
(M) breast cancer cells in 3-dimensional Matrigel culture and treated with 10 nM β-estradiol (E2) 
or 1 µM Tamoxifen (TAM) for 4 days. B. Viable cell counts of mesenchymal MCF-7M and BT-
474M breast cancer cells in 3-dimensional Matrigel culture and treated with 1 µM Tamoxifen 
(TAM) +/- 100 mM MCT1 inhibitor SR 13800 for 4 days. Results are presented as mean ± S.E.M. 
of three different experiments (n=6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary 
one-way ANOVA). 
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CHAPTER 4 
 
GPR81 REGULATES LACTATE METABOLISM IN EPITHELIAL  
BREAST CANCER CELLS 
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I. Abstract  
G-protein-coupled receptor 81 (GPR81) functions as a receptor for lactate and plays an important 
role in cancer progression. However, the expression of GPR81 and its role in the context of 
metastatic cancer have not been previously reported. Epithelial-mesenchymal transition (EMT) 
promotes metastasis by inducing invasive properties in epithelial tumors. Here, we have studied 
the expression of GPR81 in two epithelial breast cancer cell lines (MCF-7 and BT-474) and their 
respective EMT-induced mesenchymal progeny (MCF-7 M and BT-474 M). GPR81 was highly 
expressed in epithelial breast cancer cell lines and hormone-positive breast cancer tumors but was 
suppressed in post-EMT mesenchymal breast cancer cells or triple negative breast cancer (TNBC) 
tumors. To determine the role of GPR81 in epithelial breast cancer cells, we silenced the lactate 
receptor. GPR81 knockdown resulted in impaired breast cancer cell growth and led to apoptosis. 
We found that GPR81 regulated the expression of the lactate importer, monocarboxylate 
transporter 1 (MCT1), and the lactate uptake in epithelial breast cancer cells. GPR81 expression 
was crucial for breast cancer cell proliferation and survival under nutrient-limited conditions. Our 
study indicates that GPR81 might be a potential prognostic marker and therapeutic target in 
hormone positive epithelial breast cancer. 
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II. Introduction  
Breast cancer is a complex and heterogeneous disease, which includes a range of histologic 
subtypes associated with different clinical behavior and patient’s outcomes.  Invasive breast cancer 
(IBC) is the most predominant form of cancer among women worldwide and the second cause of 
cancer-related deaths in women in the United States 5,51. The most common type of IBC is luminal 
A, characterized by an adhesive epithelial phenotype and defined by the overexpression of the 
estrogen receptor α (ERα) and progesterone receptor (PR). Although Luminal A IBC is a relatively 
non-aggressive type and has a good response to endocrine therapy, failure of early detection is 
associated with metastatic disease, which in turn is responsible for the majority of deaths in breast 
cancer patients. 
Metastatic dissemination of IBC starts when cancer cells penetrate the basement membrane 
into nearby breast tissue. Invasive breast cancer cells  travel to other parts of the body through the 
lymphatic system or the circulation, ultimately leading to colonization of distant organs52. 
Epithelial-mesenchymal transition (EMT) has been proposed as an early step in the metastatic 
process8,52. EMT modifies the adhesion molecules expressed by the cell allowing detachment from 
the main tumor mass, and increases motility and invasiveness of previously indolent tumor cells 8. 
The process of EMT appears to be induced by exposure of cancer cells to an altered 
microenvironment (e.g., hypoxia, increased cytokines), sometimes in conjunction with additional 
somatic mutations 10 12. 
We previously reported that prolonged mammosphere culture induced EMT in two distinct 
epithelial breast cancer cell lines, MCF-7 and BT-474 cells, generated stable populations of 
mesenchymal cancer cells, MCF-7M and BT-474M 47,48.  More recently, we showed that EMT 
promoted a more glycolytic phenotype compared to the parental epithelial breast cancer cells that 
 
53 
 
primarily use oxidative phosphorylation to produce ATP (Chapter 3). The altered metabolic 
phenotype induced by EMT involved enhanced aerobic glycolysis along with higher rates of 
lactate production.  
Several studies have highlighted lactate as a “signaling molecule” that plays a role in cancer 
cell migration, angiogenesis, immune escape and metastasis25,37. Elevated levels of lactate within 
the tumor microenvironment have been associated with metastasis and poor prognosis of cancer 
patients 27,31,34,86–88 Additionally, lactate produced by highly glycolytic cancer cells can be utilized 
by neighboring oxidative cancer cells for ATP production, a phenomenon known as “metabolic 
symbiosis”27. Specifically, one study showed that human breast cancer tumors exhibited lactate 
accumulation ranging from 0.5 mM to 8 mM, which under some circumstances is used as an 
alternative energy source by oxidative breast cancer tumor cells28.  
Intracellular and extracellular lactate levels are determined, in part, by different isoforms 
of the lactate/H+ symporter, termed monocarboxylate transporters (MCTs). These isoforms have 
different affinities for lactate and pyruvate, which influence the direction of lactate flux79. MCT1 
has a high affinity for lactate and is primarily responsible for lactate influx. Clinical studies for 
MCT1 inhibition are being conducted as a potential anti-cancer treatment option for advanced 
solid tumors in patients with lymphoma, prostate and gastric89. In contrast, MCT4 has lower 
affinity for lactate and is primarily involved in lactate export, which contributes to the acidification 
and lactate accumulation in the tumor microenvironment 26,90. Additional important players in 
lactate shuttling between cancer cells are the lactate dehydrogenases A and B (LDHA and LDHB) 
that catalyze the reversible conversion of pyruvate to lactate.  
Previous studies have identified the cell-surface G-protein-coupled receptor, GPR81, as an 
endogenous lactate receptor. The GPR81 family of receptors consists of three highly homologous 
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members, GPR109a, GPR109b and GPR81, which are regulated by the specific agonists, 3-
hydroxybutyrate, 3-hydroxyoctanoate, and lactate, respectively 41. GPR81 has been mainly studied 
in adipocytes, in which the receptor is coupled to Gi/q. GPR81 activation by lactate decreases 
cAMP production,  which ultimately reduces lipolysis 42. Recently GPR81 has been shown to be  
upregulated in most cancers (pancreas, colon, liver, breast, cervix) and its expression levels 
associated with tumor growth and metastasis 43–46,91. In this current study, we examined GPR81 
expression in the context of metastatic transformation or EMT in breast cancer.  We provide 
evidence that GPR81 promotes lactate transport in hormone-positive breast cancer cells and its 
expression is crucial for their cell proliferation and survival.  
 
III. Results 
Endogenous Lactate Receptor GPR81 Is Highly Expressed In Epithelial Breast Cancer Cells 
In 3-Dimensional Culture 
As previously described, epithelial (E) MCF-7 and BT-474 cell lines and the corresponding post-
EMT mesenchymal (M) MCF-7M and BT-474M were cultured in a more physiologically relevant 
system using 3-dimensional Matrigel and physiological modified medium (referred as MPM 
culture). Under these conditions epithelial breast cancer cells grew as tightly adherent spheroids 
for 1 week (Figure 4.1. A; “E” boxes). The two mesenchymal cell lines also formed tight 
spheroids initially, but after 2 days began invading the Matrigel (Figure 4.1. A; “M” boxes). After 
1 week of MPM culture, cells were examined for the expression of the endogenous lactate receptor 
GPR81. Epithelial spheroids expressed relatively high levels of GPR81, whereas mesenchymal 
cells showed no or very low expression (Figure 4.1. B).  
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Figure 4.1. GPR81 expression of epithelial MCF-7 and BT-474 cells and mesenchymal MCF-
7M and BT-474M in 3-dimensional Matrigel culture.  
A. Fluorescence microscopy images of 3-dimensional structures of proliferating epithelial (E) and 
mesenchymal (M) cells in 3-dimensional Matrigel with physiological modified medium for 7 days. 
Green, Phalloidin staining of F-actin; Red/orange, nuclei counterstained with SYTOXTM orange 
nucleic acid (red). B. Real-time qPCR analysis of GPR81 in epithelial (E) and mesenchymal (M) 
cells. Results are presented as mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(ordinary one-way ANOVA). 
 
GPR81 Is Highly Expressed In Human Hormone-Receptor-Positive Breast Cancer Tissues 
To determine whether GPR81 was present in human breast cancer tumors, we analyzed 
mRNA gene expression profiles from 74 human breast cancer samples and 12 non-tumorigenic 
(NT) breast tissues (Supplemental figure 4.1. B). We grouped these samples in non-tumorigenic 
(NT), estrogen receptor positive (ER+), amplification of the human epidermal receptor growth 
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factor 2 (HER2+) and triple negative breast cancer (TNBC) according to their clinical information 
provided by the supplier. Higher levels of GPR81 mRNA were noted in hormone-positive breast 
cancer samples (ER+ and HER2+) and significantly lower levels were found in the NT and TNBC 
samples (Figure 4.2. A).  We also analyzed the relative gene expression of GPR81 by the stage of 
human breast cancer. Breast cancer stage II-III had significantly higher GPR81 expression than 
stage IV (Figure 4.2. B). Additionally, the Kaplan-Meir survival plot showed that high expression 
levels GPR81 was strongly associated with better prognosis and overall survival in breast cancer 
patients (Figure 4.2. C) (p-value = 0.0011) (n = 626)92. We also tested GPR81 expression in other 
breast cancer cell lines. Hormone-receptor positive HC1500 cells had higher expression of the 
lactate receptor compared to the TNBC MDA-MB231 cells (Supplemental figure 4.1. A). These 
results demonstrate that GPR81 is mainly expressed in hormone positive and less aggressive types 
of human breast cancer.  
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Figure 4.2. GPR81 is highly expressed in human hormone-receptor-positive breast cancer 
tissues.  
A.  Relative mRNA expression of GPR81 in NT (n=12) ER+ (n=23), HER2+ (n=14) and TNBC 
(n=11) breast cancer tissue. B. Relative mRNA expression of GPR81 in stage I (n=21), II (n=32), 
III (n=25) and IV (n=4) of breast cancer. C. Kaplan-Meier plot of estimated overall survival in 
breast cancer patients (n=626) with low expression of GPR81, below the median (black line) or 
high expression of GPR81, above the median (red line)92. Log-rank test p-value = 0.0011. Results 
are presented as mean ± S.E.M.  *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA). 
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GPR81 regulates expression of the gene involved in lactate import in MCF-7 epithelial breast 
cancer cell line 
A previous study reported that GPR81 regulates the expression of lactate transport related 
genes MCT1 and MCT4 in pancreatic cancer cells through as yet unknown mechanisms44. To 
determine the role of the endogenous lactate receptor GPR81 in the lactate metabolism of ERα- 
positive breast cancer cells, we silenced GPR81 (~60%) in MCF-7 cancer cells using siRNA 
(siGPR81) up to four days in MPM culture (Figure 4.3.A). GPR81 knockdown in MCF-7 cells 
led to a 2-fold reduction in mRNA and protein expression of the lactate importer, MCT1, but had 
no significant effect on the lactate exporter, MCT4 (Figure 4.3. B-C). In addition, GPR81 did not 
significantly alter the expression of other lactate metabolism-related genes (LDHA, LDHB, 
MCT2) (Supplemental Figure 4.2.). 
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Figure 4.3. GPR81 regulates expression of the gene involved in lactate import in MCF-7 
epithelial breast cancer cell line.  
A. Real-time qPCR analysis of GPR81, B. MCT1 and MCT4 mRNA levels in MCF-7-siNT 
(control) and MCF-7-siGPR81 cultured in 3-dimensional Matrigel with physiological modified 
medium at 72 and 96 hours after transfection. C. Western blot analysis of cell lysates from MCF-
7-siNT and MCF-7-siGPR81 cells used to detect protein expression levels of MCT1 and MCT4. 
β-actin was used as a loading control. The bars represent the mean ± S.E.M of three independent 
experiments; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
 
GPR81 regulates lactate uptake in MCF-7 epithelial breast cancer cell line  
We previously reported that the two epithelial breast cancer cell lines had higher steady 
state levels of intracellular lactate and pyruvate than the corresponding post-EMT mesenchymal 
cell lines (see Chapter 3). Given that MCT1 is primarily a lactate importer, we hypothesized that 
the reduction of MCT1 expression may affect the lactate uptake of the epithelial MCF-7 breast 
cancer cells. To test this hypothesis, we measured the intracellular lactate of non-targeted control 
MCF-7-siNT and MCF-7-siGPR81 in MPM culture using NMR analysis. MCF-7-siGPR81 cells 
had significantly lower intracellular lactate compared to MCF-7-siNT cells (Figure 4.4. A), 
indicating reduced lactate uptake of MCF-7-siGPR81 cells. Additionally, GPR81 knockdown 
resulted in higher levels of lactate in the culture medium but not control MCF-7-siNT cells (Figure 
4.4. B). We did not detect a significant change in glucose consumption (Figure 4.4. C). Taken 
together, these data suggest a role for GPR81 in the regulation of the lactate uptake of the epithelial 
MCF-7 breast cancer cells.  
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Figure 4.4. GPR81 regulates lactate uptake in MCF-7 epithelial breast cancer cell lines.  
Intracellular lactate of MCF-7-siNT (control) and MCF-7-siGPR81 measured using NMR analysis 
after 72 hours of transfection. B. Lactate concentration in the medium of MCF-7-siNT 10 nM and 
MCF-7-siGPR81 10 nM were measured after 96 hours of transfection. C. Glucose consumption 
rate of MCF-7-siNT and MCF-7-siGPR81 were measured after 96 hours of transfection. MCF-7-
siNT and MCF-7-siGPR81 cells were cultured and transfected in 3-dimensional Matrigel with 
physiological modified medium and measurements were taken after 24 hours of culture in fresh 
medium. The bars represent the mean ± S.E.M of three independent experiments; *p < 0.05; **p 
< 0.01; (ordinary one-way ANOVA). 
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GPR81 is required for cancer cell proliferation and cancer cell survival when lactate is the 
primary fuel source.  
Lactate has been previously suggested as an alternative energy source for aerobic breast 
cancer cells27,28,93. To determine whether GPR81 plays a role in breast cancer cell proliferation, 
we studied the increase in viable cell numbers and the expression of cell proliferation markers 
(taken from the OncotypeDx recurrence score assay) in control MCF-7-siNT and MCF-7-siGPR81 
cells. Silencing of GPR81 led to about 40% reduction in cell proliferation of MCF-7-siGPR81 
(Figure 4.5.A) and decreased relative gene expression of proliferation markers; Ki67, Cyclin B1, 
PCNA and STK15 (Figure 4.5. B). Furthermore, the expression of the cell apoptosis marker, 
cleaved PARP, was significantly increased by 2-fold in MCF-7-siGPR81 cells when compared to 
control MCF-7-siNT cells (Figure 4.5. C).  
In order to determine whether GPR81 expression is required for cell growth and survival, 
we cultured control MCF-siNT and MCF-7-siGPR81 cells in 3-dimensional Matrigel with 
physiological medium lacking glucose, glutamine and pyruvate and with 0.1 mM, 1 mM or 10 mM 
lactate as the main available nutrient source. Despite the significant increase in cell number of the 
MCF-7-siNT cells when cultured in medium containing only 1 mM and 10 mM lactate, GPR81 
silencing prevented cell growth under these nutrient-limited conditions. Similarly, we found that 
treatment with the MCT1 inhibitor also prevented cell growth when in MCF-7 cells were culture 
in nutrient-limited conditions.  Taken together, these data support the physiological role for GPR81 
in the regulation of lactate uptake, cell proliferation and survival of the epithelial MCF-7 breast 
cancer cells under nutrient-limited conditions. 
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Figure 4.5. GPR81 is required for cancer cell proliferation and cancer cell survival when 
lactate is the primary fuel source.  
A. Viable cell counts of MCF-7-siNT (control) and MCF-7-siGPR81 after 72 and 96 hours of 
transfection and subtracting the initial cell number. B. Real-time qPCR analysis of proliferation 
markers: Ki67, Cyclin B1, PCNA and STK15. C. Western blot analysis of cell lysates from MCF-
7-siNT and MCF-7-siGPR81 cells after 72 and 96 hours of transfection used to detect protein 
expression levels of the apoptotic maker cleaved-PARP. β-actin was used as a loading control. D. 
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MCF-7-siNT and MCF-7-siGPR81 breast cancer cells were cultured in 3-dimensional Matrigel 
with physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM 
concentration for 96 hours. E. MCF-7 breast cancer cells were cultured in 3-dimensional Matrigel 
with physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM 
concentration and treated with or without MCT1 inhibitor SR 13800 for 96 hours. Viable cell 
counts after treatment. Results are presented as mean ± S.E.M. of three independent experiments; 
*p < 0.05; **p < 0.01; ***p < 0.001 (ordinary one-way ANOVA). 
 
Additive effect of GPR81 knockdown and Tamoxifen treatment in reducing the cell 
proliferation and increasing cell apoptosis in epithelial MCF-7 breast cancer cells.  
Previously, we showed that 1 µM Tamoxifen significantly reduced the expression of 
MCT1 in epithelial breast cancer cell lines (Chapter 3). We observed here that Tamoxifen further 
reduced MCT1 gene expression in GPR81-silenced MCF-7 cells treated for 4 days (Figure 4.6.A). 
We next evaluated the effects of Tamoxifen and GPR81 silencing on cell proliferation and 
apoptosis in ER+ MCF-7 breast cancer cells. GPR81 knockdown and Tamoxifen treatment had an 
additive effect on the reduction of cell proliferation markers; Ki67 and Cyclin B1 (Figure 4.6.B), 
as well as viable cell numbers of MCF-7 cells in MPM culture (Figure 4.6. C). Additionally, cell 
apoptosis was significantly increased only in MCF-7-siGPR81 cells independently of Tamoxifen 
treatment, showed by the increased expression of the apoptotic marker cleaved PARP. These data 
suggest GPR81 regulates cell proliferation and apoptosis.  
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Figure 4.6. Additive effect of GPR81 knockdown and Tamoxifen treatment in reducing the 
cell proliferation and increasing cell apoptosis in epithelial MCF-7 breast cancer cells.  
MCF-7-siNT (control) and MCF-7-siGPR81 cancer cells were treated with or without 1µM 
Tamoxifen for 96 hours in 3-dimensional Matrigel with physiological modified medium. A. Real-
time qPCR analysis of lactate importer MCT1; and progesterone receptor PR. B. Relative mRNA 
expression of proliferation markers: Ki67 and Cyclin B1. C.  Viable cell counts of epithelial MCF-
7-siNT and MCF-7-siGPR81. D. Western blot analysis of cell lysates from MCF-7-siNT and 
MCF-7-siGPR81 used to detect protein expression levels of the apoptotic maker cleaved-PARP. 
β-actin was used as a loading control. Results are presented as mean ± S.E.M. of three independent 
experiments *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
IV. Discussion 
The metabolic changes that cancer cells undergo in order to support macromolecule 
biosynthesis, growth and survival, are collectively referred to as “metabolic reprogramming”, now 
considered a hallmark of cancer cell biology14,54. Although there is increasing attention on cancer 
metabolic reprogramming, most studies have been performed in the setting of neoplastic 
transformation and less is known how metabolic reprogramming contributes to metastatic 
transformation. For example, it has been shown that the EMT-transcription factor SNAIL mediates 
the suppression of mitochondrial respiration and enhances glycolysis in breast cancer58,73. More 
recently, we demonstrated that EMT induced a metabolic shift to a less oxidative and more 
glycolytic metabolism in two epithelial cell lines, MCF-7 and BT-474, as evidenced by increased 
glucose uptake and lactate production along with increased expression of enzymes and 
transporters47 (Chapter 3). These studies suggest that metastatic transformation or EMT facilitates 
the metabolic switch toward glycolysis.  
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Metabolic reprogramming induced by EMT was associated with a striking switch in the 
expression of the lactate transporters MCT1 and MCT4. Epithelial breast cancer cells express high 
levels of the lactate importer MCT1 and import lactate as an alternative energy source. In contrast, 
the mesenchymal cells showed a marked decreased expression of MCT1 and upregulation of the 
lactate exporter MCT4. This MCT4 upregulation was previously reported in triple negative breast 
cancer and high levels of this lactate exporter were associated with poor prognosis and survival80,94. 
As a result of the glycolytic shift induced by EMT, mesenchymal cells secrete higher amounts of 
lactate acid to the extracellular microenvironment which creates an acidic microenvironment that 
has been associated with tumor progression19. In addition, previous studies determined that 
extracellular lactate plays a critical role in cancer progression and metastasis by promoting cancer 
cell migration, immune escape and angiogenesis 31–33,35. Most recently, lactate has been shown to 
act as a “signaling molecule”, which, once imported by the cancer cell regulates intracellular 
signaling pathways like HIF1α-associated signaling39, or binding directly to the metastatic 
activator NDRG3 (N-Myc Downstream Regulated Gene 3) 40. In both cases a signaling cascade 
was triggered to promote tumor angiogenesis and tumor growth in vivo.  
Lactate has been identified as the ligand for the endogenous cell-surface G-protein-coupled 
receptor 81 (GPR81).  This lactate receptor was first discovered and mostly studied in adipocytes, 
in which lactate activates GPR81 to decrease the cAMP production to ultimately reduce lipolysis42. 
GPR81 is highly expressed  in neurons95, and when activated, it is able to modify electrical activity 
of primary neuronal cells96. Also, the activation of GPR81 by lactate has been identified as the 
initial step for an anti-inflammatory response in pancreas, liver and uterus97–99.  
More recently, GPR81 expression has been found to be upregulated in several types of 
cancer, including pancreatic, colon, liver, breast, lung and cervical cancers, and in several cases 
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high GPR81 expression was associated with tumor growth, chemoresistance and metastasis43–46. 
Our study provides the first examination of GPR81 expression in the context of metastatic 
dissemination or EMT. We showed that hormone-positive epithelial breast cancer cells highly 
expressed GPR81, but after EMT induction and transformation into triple negative mesenchymal 
cancer cells, the expression of this lactate receptor was significantly reduced. Lee et al reported 
that GPR81 expression is significantly increased in breast cancer patients compared to normal 
mammary tissues43. We also observed a significant association between GPR81 overexpression 
with estrogen receptor (ERα)-positive and human epidermal growth human epidermal growth 
factor-2 receptor (HER2) positive human breast cancer tissues as opposed to triple negative breast 
cancer. This is consistent with previous observations that ERα-positive breast cancer tissues 
overexpressed GPR8143. In addition, GPR81 was expressed at higher levels in the first three stages 
of breast cancer (Stage I, II and III) as compared to Stage IV, and GPR81 expression correlated 
with better overall survival of breast cancer patients. These findings suggest that GPR81 may be 
an important regulator in hormone-positive breast cancer and could be used as a prognostic marker 
in the progression of breast cancer.  
GPR81 was reported to regulate the expression of genes involved in lactate metabolism, 
including lactate transporters, MCT1 and MCT4, in pancreatic cancer cells44. In partial agreement, 
our study revealed that GPR81 specifically regulates the lactate importer MCT1, but not lactate 
exporter MCT4, in epithelial breast cancer cells. Oxidative breast tumor cells with high expression 
of the lactate importer, MCT1, have been reported to import and oxidize extracellular lactate, a 
mechanism that is essential for cell viability under glucose deprivation28,93,100. In fact, Park et al 
showed that epithelial breast cancer cells imported and utilized 14C-lactate for mitochondrial 
respiration 43. We previously showed that inhibition of the lactate importer, MCT1, reduced cell 
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proliferation in epithelial but not mesenchymal cancer cells when lactate was used as the primary 
metabolic substrate. Here we report that GPR81 silencing caused downregulation of MCT1 as well 
as reduced cell growth in epithelial breast cancer cells when grown in complete MPM medium. 
We previously reported that the two epithelial breast cancer cell lines contained significantly 
higher intracellular lactate and pyruvate than the two corresponding post-EMT mesenchymal cell 
lines. In the present study, we observed that GPR81-silenced cells had lower intracellular lactate 
and higher levels of lactate in MPM culture media compare to control cells, indicating reduction 
in lactate uptake. Furthermore, we found a protective effect of GPR81 against apoptosis, which 
was previously described in epithelial MCF-7 breast cancer cells, where GPR81 activation 
triggered the PI3K/Akt signaling pathway to inhibit apoptosis43. Together these results suggest a 
specific regulation of GPR81 on lactate importer MCT1, which affects cell proliferation, apoptosis 
and survival of hormone-positive epithelial breast cancer cells.  
In adipocytes, GPR81 is coupled to Gi/q which inhibits adenylate cyclase activity and 
decreases the production of cAMP. However,  a previous study did not find a significant change 
in cAMP levels when GPR81 was silenced in epithelial MCF-7 breast cancer cells43, suggesting 
that GPR81 regulates MCT1 expression by another signaling pathway in these cells.  It should also 
be noted that previous studies indicate that lactate activates GPR81 in the millimolar range (1 to 5 
mM), and in human breast cancer tissues lactate was found to be at concentrations as high as 8 
mM28, suggesting that GPR81 and downstream signaling pathways could be constantly activated 
by lactate in the breast tumor microenvironment . Further studies are needed to examine which 
signaling pathways are linked to GPR81 in epithelial breast cancer, as these pathways may provide 
targets for future development of adjuvant therapies for Luminal A breast cancer. 
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V. Supplemental figures 
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Supplemental figure 4.1. GPR81 expression in breast cancer cell lines and tissue samples.  
A. Real-time qPCR analysis of lactate receptor GPR81; lactate transporters: MCT1, MCT2 and 
MCT4 and hormone/growth factor receptors: ER, PR and HER2 in HC1500 and MDA-MB 231 
breast cancer cell lines B. Relative mRNA expression of lactate receptor GPR81 in breast cancer 
tissue samples (n=74) and non-tumorigenic breast tissue (n=12). Results are presented as mean ± 
S.E.M. of three independent experiments *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(ordinary one-way ANOVA). 
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Supplemental figure 4.2. GPR81 knockdown effect on relative mRNA expression of A. 
GPR81 homologous genes: GPR109A and GPR109B; B. lactate transporter MCT2; lactate 
dehydrogenases: LDHA and LDHB; glucose transporters: GLUT1, GLUT3 and GLUT12; and 
gluconeogenic enzymes: PCK2, FBP1 and G6PD in MCF-7-siNT (control) and MCF-7-siGPR81 
cultured in 3-dimensional Matrigel with physiological modified medium at 72 and 96 hours after 
transfection. Results are presented as mean ± S.E.M. of three independent experiments *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA). 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
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I. Summary 
Epithelial-mesenchymal transition (EMT) induces invasive properties in epithelial tumor 
cells and promotes metastasis.  Previously, we induced EMT in two distinct epithelial breast cancer 
cell lines, MCF-7 and BT-474 cells that generated stable populations of mesenchymal cancer cells, 
termed MCF-7M and BT-474M cells, respectively47,48. A previous characterization of these cell 
lines using standard 2-dimensional culture on plastic dishes and a standard tissue culture medium, 
revealed that both epithelial MCF-7 and BT-474 cells are less glycolytic than the two 
mesenchymal MCF-7M and BT-474M cell lines47. In chapter 3 we examined the degree of 
oxidative vs glycolytic metabolism in these 4 cell lines, using a more physiological culture system 
that involves both a 3-dimensional Matrigel matrix and media containing the physiological levels 
of glucose, lactate, glutamine and pyruvate, termed MPM culture. Under these MPM culture 
conditions, both epithelial and mesenchymal cell lines maintained their phenotypic features and 
they showed marked morphological and behavioral differences. We further studied the metabolic 
shift induced by EMT using the Seahorse extracellular flux technology. We found that 
mesenchymal cancer cells had significant lower levels of oxygen consumption rate (OCR) and 
increased levels of extracellular acidification (ECAR) when compared to the parental epithelial 
cell lines, confirming a glycolytic shift induced by EMT. We further examined the metabolic 
differences in lactate flux and utilization by these four cell lines. We found that EMT induced 
overexpression of the lactate dehydrogenases LDHA and LDHB. In addition, EMT-induced 
mesenchymal cells downregulated the expression of the lactate importer MCT1 and overexpressed 
the lactate exporter MCT4. We also found that intracellular lactate and pyruvate were significantly 
lower in EMT-induced mesenchymal cancer cells. Together, these changes in lactate metabolism 
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induced by EMT support the glycolytic metabolism of mesenchymal cancer cells. In contrast, we 
found that oxidative epithelial cancer cells that highly expressed MCT1 are able to import lactate 
and use it as a nutrient source to support cell growth. Furthermore, we discovered that the 
transcription factor GATA3 and ERα signaling regulate the expression of the lactate importer 
MCT1, and the treatment with both Tamoxifen and MCT1 inhibitor has an additive effect on 
reducing cell growth of epithelial cancer cells. 
In Chapter 4, we further continued our studies on lactate metabolism by examining the 
expression and role of the endogenous lactate receptor GPR81 in the context of EMT. We found 
that GPR81 is highly expressed in epithelial cancer cell lines but not in the derived EMT-induced 
mesenchymal cancer cell lines. Also, GPR81 overexpression was significantly associated with 
hormone-positive breast cancers and better overall survival of breast cancer patients. These 
findings suggest that GPR81 may be an important regulator in hormone-positive breast cancer and 
could be used as a prognostic marker in the progression of breast cancer. We observed that 
silencing of GPR81 downregulates the expression of the lactate importer MCT1, but not lactate 
exporter MCT4. In addition, GPR81 silencing caused decreased intracellular lactate, reduced cell 
proliferation and increased apoptosis in the epithelial cancer cells. Also, GPR81 expression was 
crucial for cell growth and survival of the epithelial cancer cells, when lactate was the only nutrient 
source available in the culture media. Together these findings suggest that GPR81 regulates lactate 
import through MCT1 expression by a mechanism yet to be elucidated. Furthermore, we found 
that Tamoxifen treatment and GPR81 silencing have an additive effect on reducing MCT1 
expression and cell proliferation in epithelial breast cancer cells.  
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II. Future Directions 
i. Lactate metabolism  
We found that epithelial breast cancer cells exhibited an oxidative metabolism while the 
EMT-induced mesenchymal cancer cells have an enhanced glycolytic metabolism. To gain better 
insight into how both epithelial and mesenchymal cells metabolize glucose, we propose to perform 
glucose flux studies using 13C-glucose and NMR. We will be able to determine the rates of glucose 
uptake, track the amount of glycolytic-derived lactate and other metabolites. We hypothesize that 
the rates of glucose uptake and glycolysis will be increased in the EMT-induced mesenchymal 
cancer cells. 
We also found that epithelial breast cancer cells express high levels of the lactate importer 
MCT1 and the blockage of this lactate importer with MCT1 inhibitor reduced significantly their 
cell growth when lactate was only nutrient available. To confirm the ability of epithelial cancer 
cells to import lactate across the plasma membrane and use it to fuel their oxidative 
phosphorylation, we propose to perform lactate flux studies using 13C-lactate and NMR. We 
propose to examine lactate uptake rates and lactate-derived metabolites by culturing the cells in 
glucose-deprived medium with 13C-lactate and analysis of intracellular 13C-lactate and 13C-
pyruvate by NMR. Also, we could use this approach to study how the blocking the lactate import, 
using treatments with MCT1 inhibitor or Tamoxifen or silencing of GATA3, affect the 
intracellular 13C-lactate in epithelial breast cancer cells.  
ii. Lactate transporters 
We found high levels of lactate importer MCT1 in epithelial cancer cells, whereas EMT-
induced mesenchymal cancer cells expressed high levels of lactate exporter MCT4, in either case 
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itis necessary to know whether MCT1 and MCT4 are functional transporters properly localized at 
the plasma membrane. We propose to examine the localization of these lactate transporters in 
epithelial and mesenchymal cancer cells using confocal microscopy and specific antibodies for 
MCT1 and MCT4.  
Also, we found that the transcription factor GATA3 regulates the expression of the lactate 
importer MCT1 but not lactate exporter MCT4. We propose to confirm this interaction and 
regulation using a luciferase gene reporter assay with a vector containing the sequence for GATA3 
binding site of the MCT1 promoter (with or without mutation) followed by the luciferase reporter 
gene. This approach will allow us to verify the transcriptional regulation of GATA3 on the gene 
expression of the lactate importer MCT1.  
EMT induced the overexpression of the lactate exporter MCT4 in mesenchymal cancer 
cells. We propose to examine the effects of blocking MCT4 in EMT-induced mesenchymal cells 
using specific MCT4 inhibitors. In addition, we propose to study MCT4 regulation in EMT-
induced mesenchymal cells using a signaling pathway panel of inhibitors containing 12 to 16 
inhibitors to elucidate a specific signaling cascade.  
Finally, it will be important to examine the effects of both knockdown and overexpression 
of MCT1 and MCT4, along with inhibitors of MCT1 and MCT4, on cell proliferation, growth and 
possibly metabolic adaptations in the context of orthologous transplantation of cells into the 
mammary fat pads of immunodeficient mice. 
iii. Lactate receptor GPR81  
We propose to study the localization of the lactate receptor GPR81 in epithelial and 
mesenchymal breast cancer cells by transfecting them with the plasmid pCMV6-AC-GFP 
(Origene), which contains the GPR81 ORF sequence tagged with GFP at the C-terminal region 
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(GPR81-GFP). Our preliminary studies using these plasmids indicate that GPR81 localizes at the 
plasma membrane in epithelial breast cancer cells but GPR81 is restricted to the nucleus in EMT-
induced breast cancer cells. Further studies are needed to confirm the localization of GPR81 in 
these specific compartments in the cell using control proteins at the plasma membrane or nucleus. 
We found a significant association between hormone-positive breast cancer tissues and 
cells with overexpression of GPR81. Further studies would examine whether epithelial breast 
cancer-related transcription factors (e.g., ERα, GATA3, FOXA1) stimulate GPR81 gene 
transcription. 
Previous studies on normal cells (e.g., adipocytes) revealed that the lactate receptor GPR81 
blocks adenyl cyclase to lower the levels of cAMP and increase intracellular Ca+2 levels. Although, 
previous studies showed no change in cAMP levels when GPR81 was silenced epithelial cancer 
cells43, we propose to attempt to reproduce this finding in epithelial cancer cells culture in MPM.  
If we also observe no changes in cAMP levels in response to GPR81 knockdown or 
overexpression, we propose to use pharmacological and siRNA screens to identify the signaling 
pathway(s) that is/are coupled to GPR81. 
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APPENDIX 
Appendix: Primer sets for real-time qPCR 
 
GENE 
SYMBOL 
FORWARD PRIMER REVERSE PRIMER 
TBP TTGCTGCGGTAATCATGAGG TTTTCTTGCTGCCAGTCTGG 
ZEB1 TGCACAAGAAGAGCCACAAG TGCGCAAGACAAGTTCAAGG 
ZEB2 ATGCTTTTGCCCAACTGCTG ACAGAGAGGGCAGGAAAAGTTC 
CDH1 TTGAACGAATGGGGCAATCG ACCAGCAACGTGATTTCTGC 
GATA3 ATGAAGCCTAAACGCGATGG TGAGCTCCTTTGCAAAGTGG 
VIM TCTCAGCATCACGATGACCTTG TTGCGCTCCTGAAAAACTGC 
CD24 AACTAATGCCACCACCAAGG ATGCAGAAGAGAGAGTGAGACC 
CD44 AAGGTGGAGCAAACACAACC TCGACTGTTGACTGCAATGC 
GPR81 TCATTGTGGCCTTTGTGCTG AATCAGCCACGGCCAAATTG 
GPR109A AAGATCTCCAATCGGACAGCAG AATTTGCACCGCCATTCTGG 
GPR109B TGGTGCTCTTCATGTTTGCC TGATGGCTGCTGTCCAATTG 
ERα TTGAAACACAAGCGCCAGAG TTTGATCATGAGCGGGCTTG 
PR TGCAGACTTTACAGGCAAGC AGGGCAAAGAGGACAAATGC 
HER2 TTTTGGGGCCAAACCTTACG ACATCAATGGTGCAGATGGG 
Cyclin B1 AAGGCGAAGATCAACATGGC TTTGGCCTGCAGTTGTTCAC 
KI67 TGCAGCAAAACAGCCATCTG TTCCTGGGCGTTTTTGCTAC 
PCNA AACCTGCAGAGCATGGACTC TCATTGCCGGCGCATTTTAG 
STK15 AATTCTTCCCAGCGCATTCC TGGTTGCCTGCAATTGCTTC 
MCT1 TGGTGACCATTGTGGAATGC AATTAGGACGACGCCACATG 
MCT2 AGCAGAAATGCCACCAATGC AAGCTGCTCCAACCACAATC 
MCT4 TTCGGCTGTTTCGTCATCAC TCCCAAACTCCTGTATGAGCTC 
LDHA CATGGCAGCCTTTTCCTTAG ATGACCAGCTTGGAGTTTGC 
LDHB AACATGGCGACTCAAGTGTG AGGCACTTTCAACCACCATC 
PCK2 TGCGTATTATGACCCGACTG TCAGGGTTTTCTCTGGGTTG 
FBP1 AAGTCATCCTTTGCCACGTG TTTACCCCTTTTCTCCGGTTCC 
G6PD TGCCCGAAAACACCTTCATC TCACTCTGTTTGCGGATGTC 
GLUT1 ATGCCGATTTGGTTCCTGTG TTTTCTGAGTGCCTGCTGTG 
GLUT3 TTGACGGACAAGGGAAATGC TTGAATTGCGCCTGCCAAAG 
GLUT12 AAAGCAATGAGGCAGCTAGC ATGTTTTGCTGCCGACATGG 
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